Entities

Previously worked as a proprietary trader at InCommodities and an investment analyst at M+ Invest.

Biotechnology entrepreneur whom Genesys Capital appointed venture partner inJanuary2022. The current main manager directory omits him, and its announced future GP transition is not assumed completed. Neurenati’s current biography identifies him as its CEO and chair, with a Université Laval chemistry doctorate, Stanford postdoctoral fellowship and a joint UQAM/Paris-Dauphine executive MBA.

Office manager at Genesys Capital since2023. Previously worked in human-resources project management and client and office services at a Canadian law firm. Holds a Bachelor of Arts from Toronto Metropolitan University.

Co-founder and managing director of Genesys Capital. Previously a senior investment manager at MDS Capital and a researcher in Peter St George-Hyslop’s University of Toronto laboratory investigating Alzheimer’s disease genetics. Holds biochemistry and MBA degrees from Queen’s University.

Associate at Genesys Capital and a Chartered Professional Accountant. Her manager biography describes experience in fund accounting, financial and investor reporting, operations and audit coordination, including work at a fund administrator and a venture-capital firm.

Senior vice president of finance at Genesys Capital, which she joined in2007. A Chartered Professional Accountant with a Master of Accounting from the University of Waterloo, she has investment-fund finance, administration and operations experience.

Principal at Genesys Capital, which she joined as an associate in2020. Works on biotech and medtech sourcing and diligence. Previously managed intellectual-property and commercialization opportunities at the Hospital for Sick Children. Holds a University of Toronto medical-faculty doctorate and a McMaster health-science degree.

Co-founder and managing director of Genesys Capital, established in2000. Previously an investment manager at MDS Capital. His official biography identifies a molecular-neurobiology master’s from McMaster and an MBA from Queen’s University, along with life-science company-building and board experience.

Partner and chief financial officer at Genesys Capital, which she joined in2002. Leads finance, operations and governance and works on fundraising and limited-partner relations. Holds commerce and MBA degrees from Queen’s University and has served in Canadian venture-capital industry governance.

Associate at Genesys Capital. A PhD-trained immunologist with microbiology and immunology degrees from Dalhousie University, she previously worked in venture and technology development at CCRM and completed a postdoctoral fellowship at adMare Bioinnovations.

Genesys Capital is a Toronto-based Canadian venture-capital manager founded in2000 by Damian Lamb and Kelly Holman. It invests in and helps create early-stage life-science companies in biotechnology, pharmaceuticals and medical technology, working with scientific founders, universities and research institutes. The firm’s current website reports more than$400M raised across six early-stage venture funds,44 companies and20 exits; these are aggregate manager statistics rather than a single fund size or independently verified performance ranking. Its relevance to neuroscience and deep technology includes Enspire DBS Therapy’s investigational neuromodulation for chronic stroke, Functional Neuromodulation’s work on cognitive and memory disorders, EBT Medical’s peripheral nerve stimulation, and Adapsyn Bioscience’s use of artificial intelligence and genomic/metabolomic data for natural-product drug discovery. Other named portfolio companies work on intracellular drug delivery, MRI-guided ultrasound ablation, wearable blood-flow sensing, genomic interpretation, cryopreservation and drug development. Current public staff include managing directors Damian Lamb, Kelly Holman and Jamie Stiff, partner and CFO Jennifer Williams, finance executive Lisa Low, principal Sarah Farr, associates Stephanie Legere and Laurie Mak, and office manager Christine Thoburn. A January2022 Maxime Ranger venture-partner appointment is retained with historical qualification because he is absent from the current staff panel; the planned transition to general partner is not assumed completed. Institutional limited-partner records confirm Genesys Ventures II and a final CAD107M size for Genesys Ventures III. Its June2025 Fund IV announcement described an upcoming closing without disclosing the fund amount or proving that exact day was the final close. The separate Genesys University Seed Fund announced in July2026 had already held a first close with more than CAD30M of commitments, while accepting additional commitments toward a CAD40M target. Those limits are distinct from exact final fund size. The firm is an actual co-lead of Feldan Therapeutics’ completed USD21M Series B announced4September2024. Historical exits and divestments in the website’s past-success panel are distinguished from continuing holdings.

Jennifer R. Weiss is chief financial officer of Glenview Capital Management. Its September2026 SEC ADV lists her CFO title from March2025 and CRD4824128. Her self-published professional profile confirms the exact Glenview affiliation and Ithaca College education. Earlier external descriptions of controller duties are historical rather than a substitute for her current registered title.

Mark Joseph Horowitz is president, general counsel and chief compliance officer of Glenview Capital Management according to its September2026 SEC ADV. He joined the firm in2004 after management work at Axiom Legal Solutions and corporate and securities law practice at Cravath and Brobeck. He earned a law degree from Harvard and an economics degree from the University of Michigan. He is distinct from the Stanford engineer, film director and other similarly named individuals.

John David Rodin is chief executive officer of Glenview Capital Management from March2026 according to its current SEC ADV. He first joined Glenview in2002, became research director and partner, left to lead Fantex Brokerage Services, and rejoined in2015. Earlier Glenview roles included co-president. He previously worked in investment banking and institutional equity sales at Goldman Sachs and graduated from Columbia University.

Glenview Capital Management, LLC is a New York investment manager founded by Larry Robbins in 2000. It manages private pooled investment funds using fundamental investment research and engages with companies on long-term value creation, capital allocation and corporate strategy. Its healthcare and technology investments include semiconductor proteomics company Quantum-Si and ultrasound imaging and AI company Butterfly Network through verified 2021 PIPE financings. The firm is SEC-registered under CRD137640 and SEC801-73695. Its September15,2026 Form ADV identifies John David Rodin as chief executive officer since March2026, Lawrence Michael (Larry) Robbins as chief investment officer, Mark Joseph Horowitz as president, general counsel and chief compliance officer, and Jennifer R. Weiss as chief financial officer. Older biographies still describe Robbins as CEO; those historical titles are qualified against the current filing. The ADV reports six principal fund reporting groups and their separately named feeder vehicles, including an internal employee fund-of-funds and the internal-capital Cassius fund launched in August2026. Fund assets under management, NAV, employee investments, sponsor equity and transaction trust proceeds are not treated as independently closed external LP fundraising. Longview Acquisition SPAC entities and Glenview managed legal fund buyers remain distinct. The firm does not publish an accessible complete public staff directory; only verified named public affiliations are recorded.

Jenny He is the founder and general partner of Position Ventures and the managing member of its legal adviser and Fund II general partner. She works with early-stage founders on positioning and communications strategy, drawing on a career helping both first-time and established founders tell their companies' stories. The firm combines venture investing with support for hiring, fundraising and partnerships.

Liu Jiang founded Sunflower Capital in2022 after investing at Sequoia Capital. The firm backs AI and enterprise infrastructure, healthcare technology and physical-world businesses at the earliest stages. Its own website identifies Jiang on its current team; SEC Fund I filings independently name Jiang managing member of its general partner. Prior investments before Sunflower are explicitly distinguished from institutional fund investments.

Maximillian Wang, published by Sunflower Capital as Max Wang, is on the firm’s current team. The manager’s own linked professional profile describes an engineering generalist with wildfire-technology work and Stanford University education. The current website does not publish a more specific investment title or appointment date, so neither is inferred.

Mo Punjwani is a partner of Sunflower Capital. His April2025 direct announcement says he joined the firm alongside his operating work at Mural Health, applying experience from building companies to early-stage investing. His publicly published background includes General Catalyst, Morgan Stanley and J.P. Morgan, and Boston College education. No unsupported current operating-employment status is inferred.

Alex Kaufman is listed as an APA Venture Partners partner focused on enterprise SaaS and healthcare by the organizer of a September5,2025 San Francisco venture-investor event. Verizon’s own2022 review confirms his earlier Principal appointment that February. His identity is not assumed to be the Charles Kaufman named in APA’s2021 SEC filing.

Charles Kaufman is named as a manager of APA VP Management Company LLC in APA Venture Partners Fund I’s December2021 SEC Form D. The2022 amendment does not name him. His relationship to APA partner Alex Kaufman is not independently established, so no alias merge, portrait assignment or current executive tenure is inferred.

Paul Kirincich is identified as an APA Venture Partners general partner by GreyscaleAI’s previously published management biography and as a manager of the fund-management company in SEC2021/2022 filings. His published background spans technology finance, post-IPO Netflix leadership and CFO experience at One Medical and other companies, with a Wesleyan BA and Wharton MBA. The former GreyscaleAI team page now redirects to404; its dated public biography is retained as historical source evidence. GreyscaleAI’s January23,2025 SEC disclosure names Paul Kirincich as Executive Officer and Director. Its formerly published management biography names him CFO; that page now returns404 and does not establish current2026 tenure. His APA affiliation and existing biography are preserved.

BLING Capital is a founder-led Swedish venture investor established in 2022 to back diverse and underrepresented founders at the earliest stages. It invests in scalable companies with sustainable business models addressing large markets, including AI applications, satellite technology, energy software, precision agriculture and other technology businesses. Initial investments range from SEK 300,000 to SEK 2 million, and the team works with founders as a long-term partner through BLING’s entrepreneurial network.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Managing Partner, Redstone Nordics; Marginum explicitly lists him in its Executive Advisory Board, not as an employee or statutory board director.

Instinct is a personal AI assistant operated by Spear Street Technology, Inc. Users text or call the assistant, which uses websites, phones and computers to complete tasks across their applications and accounts. Published examples include disputing bills, sending gifts, ordering groceries, scheduling appointments and planning trips. It connects personal context such as email, calendars and payment methods to handle multi-step tasks and follow up on unfinished work.

Former Robinhood team lead; distinct from the Bionics Institute development manager.

AI researcher and former Datagen founder; previously worked with the CTO of NVIDIA. Distinct from the Factual/Applied Semantics founder of the same name.

Founder of Cyberstarts.

General Partner at Cyberstarts.

Previously served in Unit 8200 and held technology leadership roles.

CTO of Armis.

Lead author of Reflexion and previously a research scientist at Sierra.

CEO of Armis.

Previously worked on machine learning and natural-language processing at Alation.

Sunflower Capital is a US early-stage venture capital firm founded by former Sequoia Capital investor Liu Jiang. It partners with technical founders before product launch and supports AI, enterprise and developer infrastructure, healthcare technology, robotics and critical industries. Its own published team names Liu Jiang, Max Wang and Mo Punjwani. Sunflower’s April 2025 founder announcement described USD250 million in combined capital across Funds I and II; this aggregate is not independently assigned to each vehicle. Its institutional portfolio includes AI companies Cohere, Ollama, E2B, Slingshot AI, and Applied Compute, physical-AI company Sunday Robotics and healthcare software company Ease Health. The portfolio marks selected entries with an asterisk; earlier founder and prior-firm investments are not assumed to be current institutional cash checks. Asterisked entries are excluded from newly inferred institutional relationships pending specific buyer proof. Bridge Neurotech’s October 2026 founder letter confirms Sunflower participated in its actual USD13.5 million financing; individual allocation and exact closing day are undisclosed. Sunflower is a separate firm from Costanoa Ventures, which is also named in Rerun’s 2025 financing; a prior Costanoa record whose display name had been overwritten is preserved and corrected separately. Its exact legal manager is Sunflower Capital Investment Management LLC, SEC exempt reporting adviser CRD323327. SEC notices verify fully sold capital of USD64.525 million for Fund I as reported in November2022, USD150 million for Fund II in April2025, and USD3.68 million for SPV I in December2022. Exact final closing days are not disclosed. Later founder-stated combined capital and current fund asset values are recorded with their source dates, without inventing independently allocated fund sizes.

Sylvia Goh is Senior Vice President of Finance and Compliance at Altara Ventures, overseeing financial management and regulatory compliance.

Karen Ng is Finance Executive at Altara Ventures, supporting financial operations and investment administration.

Chwee Chen is Fund Admin Executive at Altara Ventures, supporting fund administration and investment operations.

Bryan Ngadimin is an Investor at Altara Ventures with experience in public equities, restructuring, fundraising and operations. His biography describes operating work at Gojek and founding a venture-backed startup. He studied finance at Harvard University and computer science at the University of Rochester.

Jamaine Lee is an Investor at Altara Ventures, focused on early-stage Southeast Asian opportunities. She previously worked with Gentree in the Philippines and Argor Capital, formerly Go-Ventures, in Indonesia. She holds a Banking and Finance business degree from Nanyang Technological University.

Teddy Peralta is an Investor at Altara Ventures. He previously invested at Arbor Ventures and worked in product roles at Clair and Dashlabs.ai, and with Kaya Founders in the Philippines. He holds a University of Pennsylvania degree in Economics and Cognitive Science.

Jun Ho Bae is an Investor at Altara Ventures, which he joined in2025. He previously led APAC investments at Tenity and Plug and Play and worked with AirAsia’s corporate venture arm. He studied at Washington University in St.Louis. An exact appointment day is not disclosed.

Gavin Teo is a General Partner of Altara Ventures. His biography describes prior investment roles at B Capital and Comcast Ventures and product work at Zynga. His current own biography identifies portfolio board affiliations spanning health technology and enterprise and consumer software.

Dave Ng is a General Partner of Altara Ventures. His biography describes prior leadership of Southeast Asia at Eight Roads Ventures, founding-team venture investing at B Capital, and strategy and operating roles at Oracle and Zuora. Earlier portfolio roles belong to those employers and are not assumed to be Altara investments.

Tan Chow Boon is a General Partner of Altara Ventures. He co-founded Omni Electronics and founded Eteq Components, subsequently consolidated within Omni Industries. He has managed Southeast Asian growth-stage private equity funds since2006 and studied mechanical engineering at the National University of Singapore.

Seow Kiat Wang is a General Partner of Altara Ventures. He co-founded Omni Electronics in1991, served as Operational Director of Omni Industries, and has managed Southeast Asian growth-stage private equity funds since2006. His engineering degrees are from the National University of Singapore.

Koh Boon Hwee is Chairman and General Partner of Altara Ventures. Its biography describes his leadership at Hewlett-Packard, co-founding Omni Industries, and prior chairmanships of DBS, Singapore Airlines and Singtel. He studied at Imperial College and Harvard Business School.

Altara Ventures is a Singapore-based venture capital firm backing early-stage companies across Southeast Asia, South Korea and selected global markets, including the United States and India. It typically leads Series A and Series B rounds and supports founders through board participation and operating experience. Its strategy spans financial services, consumer platforms, enterprise software, healthcare, supply chains and education. Relevant published investments include Senseye’s ocular analytics and machine-learning research for mental-health assessment, AI-driven mathematics education company Clevai, enterprise software provider Servis.ai, and healthcare companies Kyan, Med247, Klinik Pintar and Reach52. The firm launched in2020; the underlying Altara Ventures Fund L.P. was formed in2019 and formerly named Credence Ventures Fund L.P., according to its SEC filing. Its current own portfolio attributes Senseye’s Series A investment to2019, a predecessor-era date. The exact legal investor vehicle for that historical investment is not asserted from the later brand alone. The firm’s published USD130M assets under management and USD3–5M initial check range are distinct from independently verified fund closings and individual portfolio tickets.

Spark Growth Ventures board advisor with venture-capital, startup mentoring, entrepreneurship education and impact-investing experience. The firm's biography describes earlier general-partner work at IDG Ventures and degrees from Stanford and Harvard Business School.

Spark Growth Ventures board advisor specializing in SaaS pricing, commercial strategy and portfolio operations. Spark's biography describes founding Pricing I/O and prior portfolio-operations work at Vista Equity Partners.

Spark Growth Ventures board advisor with investing, operating and entrepreneurship experience spanning technology, digital media, financial services and education. The firm's biography describes earlier roles at Schibsted and JPMorgan and studies at Dartmouth and Harvard Business School.

Spark Growth Ventures board advisor with business leadership experience in medical devices, consumer goods and telecommunications. Spark's biography describes earlier growth and commercial leadership at Exact Sciences, Align Technology, Bharti Airtel and Procter & Gamble.

Spark Growth Ventures board advisor with experience in finance, strategy, technology investing and investment banking. The firm's biography describes roles at Juul Labs and earlier financial-market work at Millennium, Corvex, KKR and Goldman Sachs.

Spark Growth Ventures board advisor with experience in marketing, digital services and general management across financial services and consumer technology. Spark's biography describes earlier leadership at PenFed, AARP, Capital One and Sabre.

Spark Growth Ventures board advisor and technology executive with experience in product development, technology partnerships, growth and monetization. His affiliation and original portrait are published in the firm's own advisory directory.

Spark Growth Ventures board advisor with business ownership, accounting, investing and board experience. The firm's biography describes his association with Mor Furniture and private-company investing; these personal investments are not automatically attributed to Spark.

Spark Growth Ventures is a San Diego-based venture investment platform backing early-stage technology companies, including AI, healthcare technology and medical imaging. Its own directory publishes founder and managing partner Hem Suri and eleven board advisors. Its community model offers deal-by-deal investment opportunities without a blanket precommitment. The January 2026 SEC adviser filing identifies the legal manager as Spark Venture Capital, LLC, doing business as Spark Growth Ventures, and lists 38 distinct private investment vehicles. Those legal series are recorded individually; their asset values are not treated as fresh fund closes. The firm's own portfolio identifies a May 2023 Pre-Series C investment in Promaxo. Exact ticket size and closing day are undisclosed. Founding year and aggregate committed capital remain unverified.

Spark Growth Ventures board advisor with experience in consumer technology, data organizations, product strategy and artificial intelligence. Spark's published biography describes previous data and research leadership at Meta and Intuit.

Spark Growth Ventures board advisor and technology entrepreneur. The firm's biography identifies BoardVitals and PathologyWatch as businesses he founded and led, with experience in healthcare technology, AI and computer engineering.

Spark Growth Ventures board advisor with portfolio-management experience across technology, software, fintech and AI. The firm's biography also describes earlier strategic work at eBay/PayPal and management consulting.

Founder and managing partner of Spark Growth Ventures. The firm's biography describes investment, operating, board and investment-banking experience across technology and healthcare, with degrees from Harvard Business School, the University of Illinois and IIT Delhi.

Abigail Risse is a mechanical engineer and venture investor named in an earlier Cencora Ventures external Cerity team roster. Her University of Massachusetts engineering alumni profile describes her work at Cerity Partners Ventures in corporate venture capital. Her September 2023 RESI speaker biography described her earlier Hyperplane investing role across healthcare, supply chain and enterprise technology, with a technical background in prosthetics, orthopedics, robotics and engineering at iRobot. That Hyperplane affiliation is historical. Her individual Cerity profile currently redirects to its general team page and the current live Cencora roster omits the external team, so current employment and fund assignment are not asserted as confirmed. The authentic portrait is extracted unchanged from her named 2023 conference biography.

Colin Tasi is a Boston-based Senior Principal at Cerity Partners focused on early and growth-stage biotechnology, digital health and pharmaceutical manufacturing companies. His current own biography describes earlier work at Touchdown Ventures and investment experience with RA Capital and Valtruis. He completed emergency medicine residency at Massachusetts General Hospital and Brigham and Women’s Hospital, holds an MD from Dartmouth’s Geisel School and an MBA from Tuck, and studied biological chemistry and mathematics at Connecticut College. An earlier Cencora Ventures roster names him in the external Cerity team; ongoing fund assignment is unconfirmed because the live English page omits that team.

Jenni Zilka is a Cencora healthcare and pharmacy executive named on an earlier Cencora Ventures team roster. Frist Cressey Ventures’ February 18, 2026 Collective announcement identifies her current title as Vice President of Strategic Partnerships at Cencora. Earlier Cencora publications described her as President of Good Neighbor Pharmacy and a leader of independent community pharmacy programs and services. Those older pharmacy titles are preserved as historical context. Her current fund assignment is unconfirmed because the live English Cencora Ventures page now names Raj Kapadia and Neil Kayal.

Kindra Tatarsky is a Partner at Cerity Partners and leads its healthcare venture practice, according to her own current firm biography. She joined Cerity in 2024 through its merger with Touchdown Ventures, where she had worked since 2018 across corporate venture programs in healthcare, industrials, food and agriculture, IT and media. Earlier experience included corporate development at Nielsen, startups and equity research. She is a CFA charterholder and earned a BA in English with a business minor at UCLA. An earlier Cencora Ventures roster names her in its external Cerity team; the current live English page omits that team, so ongoing fund assignment is unconfirmed.

François Mandeville is Cencora’s Executive Vice President and Chief Strategy and M&A Officer. His own corporate biography explicitly says he leads Cencora Ventures LLC alongside enterprise strategic planning, corporate development, deal sourcing and acquisition integration. He joined Cencora in 2024 after serving as Chief Development Officer at Johnson Controls and leading life-sciences business development at Danaher. Earlier work spanned Strand Life Sciences, Hewlett-Packard and Agilent Technologies. He holds an electrical engineering degree from École Polytechnique de Montréal. His current corporate oversight is distinguished from the two people named on the fund’s operational team page.

Jason Dinger is a healthcare strategy and innovation executive named on an earlier Cencora Ventures team roster. RISA Labs’ January 13, 2026 financing announcement identifies him as Cencora Senior Vice President of Strategic Execution. His 2022 AMCP speaker biography described him as AmerisourceBergen Senior Vice President of Strategy and Innovation, with prior Ascension product innovation leadership and CEO roles at MissionPoint and Dispensary of Hope. He earned a Vanderbilt undergraduate degree in public policy and a doctorate in international leadership, policy and organizations. The live English fund roster now names Raj Kapadia and Neil Kayal, so his earlier fund role is retained with current program assignment unconfirmed.

Neil Kayal is named on the current Cencora Ventures team page. His Conference Board speaker biography identifies him as Vice President of Strategy and Corporate Development at Cencora, working on enterprise strategy, complex mergers and acquisitions and portfolio optimization, including the MWI and Covetrus merger. His earlier experience includes strategy and commercial leadership at Danaher. He holds a PhD in Bioengineering from Temple University and a Master of Liberal Arts in Management from Harvard Extension School. The original portrait is published by the Conference Board beside his named Cencora biography.

Rajan Kapadia, also published as Raj Kapadia, is named on the current Cencora Ventures team page. Cencora strategy leader François Mandeville announced his appointment as Senior Vice President of Strategy Development and Business Development. His earlier self-written Clinical Lab biography described more than two decades of experience across life sciences and diagnostics and his then role as Vice President of Global Sales and Marketing at Integrated DNA Technologies. That 2022 title is historical. The authentic named portrait comes from that author biography; unrelated pharmacy and athenahealth executives with similar names are excluded.

Cencora Ventures LLC is the corporate venture capital program of Cencora Inc., launched in 2022 as AB Health Ventures under AmerisourceBergen. The program adopted the Cencora name after its parent renamed in August 2023. Its published USD150 million initial allocation is corporate investment capital, rather than a verified external LP fundraising close. It backs emerging healthcare companies and provides commercial support across pharmacy and distribution, product commercialization, clinical development and clinical practice, with an emphasis on early and middle stages in the United States and Western Europe. Its actual portfolio includes healthcare AI and clinical data companies Atropos Health, RISA Labs, Lumata Health and Acclinate, alongside House Rx and Sempre Health. Current live English team pages name Raj Kapadia and Neil Kayal; Cencora’s own leadership biography separately identifies François Mandeville as the executive leading Cencora Ventures LLC. Earlier roster versions named Jason Dinger, Jenni Zilka and an external Cerity Partners team; their fund assignments are explicitly time-qualified because the current page omits them. Parent investments made before the program launched are excluded from this unit’s portfolio attribution.

Kevin Rakin has served on Quantum-Si public vehicle board since June2020 and was HighCape Capital Acquisition CEO June2020–June2021. He cofounded HighCape in October2013 and previously led Shire Regenerative Medicine, Advanced BioHealing and Genaissance Pharmaceuticals, with Columbia and Cape Town degrees.

Amir Jafri joined Quantum-Si board in September2023. His issuer biography identifies him as Immunicom founder and president/CEO since2013, with prior West Health Institute, Cardinal Health and healthcare-startup operating experience and a chemistry/biology degree from Houston Christian University.

Brigid A. Makes has served on Quantum-Si board since June2021. Her issuer biography confirms her Vivani Medical CFO tenure ended August2025. Prior financial leadership includes Miramar Labs, AGA Medical and Nektar Therapeutics, with Bentley MBA and McGill commerce degrees.

John Patrick Kenny, known as Jack Kenny, joined Quantum-Si board in May2023. He was Meridian Bioscience CEO October2017–June2023, after Siemens Healthcare and Becton Dickinson leadership, and holds a Kettering University management-systems degree.

Scott Mendel joined Quantum-Si board in May2023. He formerly served as GenMark Diagnostics CEO, COO and CFO, The Active Network CFO and GE Healthcare IT CFO. He holds Indiana finance and Northwestern Kellogg business degrees.

Charles Kummeth is chairman of Quantum-Si since May2024 and a former Bio-Techne president and chief executive from April2013 to February2024. Earlier roles included Thermo Fisher and 3M. He holds engineering, computer-science and business degrees from North Dakota, St Thomas and Minnesota.

Paula Dowdy joined Quantum-Si board in March2024. She formerly led Illumina EMEA August2016–January2023 and previously held senior Cisco leadership positions. She has a Berkeley history BA and Pepperdine MBA.

Benjamin A. Garcia obtained his BS in Chemistry at UC Davis in 2000, where he worked as an undergraduate researcher in Prof. Carlito Lebrilla’s laboratory. He received his PhD in Chemistry in 2005 at the University of Virginia under Prof. Donald Hunt and then was an NIH NRSA Postdoctoral Fellow at the University of Illinois under Prof. Neil Kelleher from 2005-2008. From there Ben was appointed as an Assistant Professor in the Molecular Biology Department at Princeton University from 2008-2012, until his recruitment as the Presidential Associate Professor of Biochemistry and Biophysics at the University of Pennsylvania Perelman School of Medicine in 2012, promoted to full Professor in 2016, and named the John McCrea Dickson M.D. Presidential Professor in 2017. Ben moved in the summer of 2021 to the Washington University School of Medicine in St. Louis to become the Raymond H. Wittcoff Distinguished Professor and Head of the Department of Biochemistry and Molecular Biophysics. The Garcia lab has been developing and applying novel proteomic approaches and bioinformatics for interrogating protein modifications, especially those involved in epigenetic mechanisms such as histones during human disease, publishing over 450 publications. He is presently an Associate Editor of the Analytical Chemistry, and Mass Spectrometry Reviews journals; and serves on the editorial boards for the Molecular Omics, the Journal of Proteome Research and the Molecular and Cellular Proteomics journals. He is the President-Elect of the U.S. Human Proteome Organization (HUPO), on the HUPO Governing Council/Executive Committee and the Chair-Elect of the American Chemical Society (ACS) Analytical Chemistry Division. Ben has been recognized with many honors and awards for his mass spectrometry research including the American Society for Mass Spectrometry (ASMS) Research Award, a National Science Foundation CAREER award, an NIH Director’s New Innovator Award, the Presidential Early Career Award for Scientists and Engineers (PECASE), an Alfred P. Sloan Fellowship, the PITTCON Achievement Award, the Ken Standing Award, the ACS Arthur F. Findeis Award, the ASMS Biemann Medal, the HUPO Discovery in Proteomic Sciences Award, the Eastern Analytical Symposium (EAS) Outstanding Achievement in Mass Spectrometry Award and was named a Fellow of both the American Chemical Society and the Royal Society of Chemistry.

Dr. Gloria M. Sheynkman is an Assistant Professor at the University of Virginia, holding a primary appointment in Molecular Physiology and Biological Physics, secondary appointment in Biochemistry and Molecular Genetics, and is a member of the UVA Comprehensive Cancer Center. She earned her B.S. in Biochemistry from the University of Notre Dame and gained early industry experience in the Analytical Development department at Gilead Sciences. She went on to train with Dr. Lloyd Smith—the inventor of automated Sanger sequencing that contributed to the Human Genome Project—where she earned her Ph.D. in Chemistry at the University of Wisconsin–Madison. Following her doctoral work, she trained with Dr. Marc Vidal at the Dana-Farber Cancer Institute and Harvard Medical School, where she advanced high-throughput functional proteomics strategies to characterize proteoforms involved in both normal physiology and disease. Building on this foundation, Dr. Sheynkman now leads a highly interdisciplinary research group that combines advanced mass spectrometry, long-read RNA sequencing, and single-molecule protein sequencing to map and characterize diverse “proteoforms”—protein isoforms arising from nature’s “variations”, such as alternative splicing and post-translational modifications. Her team employs machine learning and integrative network biology to uncover how these proteoforms drive complex diseases, including cardiovascular disease and cancer. A recipient of numerous honors—including the American Society for Mass Spectrometry (ASMS) Emerging Investigator distinction and the Tomas A. Hirschfeld Award from the Federation of Analytical Chemistry and Spectroscopy Societies (FACS)—Dr. Sheynkman has published over 40 peer-reviewed papers in her relatively short time as a faculty member. She is active in multiple professional organizations, including the American College of Medical Genetics (ACMG), American Society of Human Genetics (ASHG), Consortium for Top-Down Proteomics (CTDP), Human Proteome Organization (HUPO), and ASMS. She has chaired prominent conference sessions, serves on several NIH study sections, and her research is continuously supported by multiple NIH grants and additional external awards. In her advisory roles, Dr. Sheynkman brings extensive expertise in bridging genomics with proteomics and a forward-looking perspective on the future of protein measurement technologies.

Lindsay Thompson serves as the Chief Human Resources Officer of Quantum-Si, where she leads all aspects of people operations, recruitment, culture and compensation/benefits. She has been with the company full time since June 2021 but was previously supporting the company while under the 4Catalyzer incubator since June 2019. Prior to that, Ms. Thompson served in various HR capacities in banking, financial services, distribution, manufacturing and insurance. Ms. Thompson received her B.S. in Business Administration and currently holds her SHRM (Society for Human Resources Management) certification.

Christian LaPointe, PhD has served as Quantum-Si’s General Counsel since November 2020. Prior to joining Quantum-Si, Dr. LaPointe served as General Counsel at ArcherDX, Inc., a genomics company, from January 2015 to August 2019, and as Deputy General Counsel at ArcherDX from August 2019 to October 2020. Dr. LaPointe also served as General Counsel to Celsee, Inc., a single cell analysis solutions provider, from August 2019 to June 2020. Previously, Dr. LaPointe was General Counsel at Thrive Bioscience, Inc., a cell culture instruments and software company, from August 2014 to July 2019, General Counsel of the Enzymatics enzyme solutions unit of QIAGEN N.V., from March 2013 to January 2015, General Counsel of Axios Biosciences, LLC, an oncology drug discovery company, from December 2012 to December 2014, and a litigation attorney at the law firm Sherin and Lodgen LLP from April 2012 to March 2013. Dr. LaPointe received his B.S. in biochemistry from the University of New Hampshire, his PhD in biochemistry from Dartmouth College and his J.D. from Suffolk University Law School.

Mr. Keyes brings over 25 years of experience in senior financial positions providing financial leadership for emerging and evolving public and private companies. Previously, he served as the Chief Financial Officer of Spinal Elements, Inc., a private equity backed medical device company. Prior to Spinal Elements, Mr. Keyes was the Chief Financial Officer of Custopharm, Inc., a private equity backed developer of generic sterile injectable pharmaceuticals, where he helped lead the company through rapid commercial growth and successful acquisition by Hikma Pharmaceuticals. Prior to Custopharm, Mr. Keyes held a variety of leadership roles in life science companies in finance, accounting, and mergers and acquisitions support, and he started his career in public accounting. Mr. Keyes has also served on the board of directors of CNS Pharmaceuticals, Inc., a public clinical stage biotech company, since June 2018. Mr. Keyes earned a B.A. degree in accounting from Western Washington University and is a certified public accountant.

Mr. Hawkins brings over 25 years of experience at the world’s leading life science and diagnostics companies as an accomplished business leader and inventor. Prior to Quantum-Si, he was President and Chief Executive Officer of Truvian Sciences, Inc. where he led the evolution of the company’s benchtop blood testing system from a product concept through technology feasibility and into late-stage development. Prior to Truvian, Mr. Hawkins led the Reproductive and Genetic Health Business Unit at Illumina, Inc., where he oversaw the rapid global growth of next-generation sequencing into new and emerging markets. During his Illumina tenure, the business unit more than doubled in revenue and established clear market leadership across every major product line and geographic region. Before Illumina, Mr. Hawkins held roles of increasing responsibility across multiple functional areas for GenMark, Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an MBA from Keller Graduate School of Management. He is co-inventor on more than 10 issued or pending patents spanning consumables, instrumentation, optics, manufacturing methods and designs.

Venture affiliate who joined BMP in 2014 to focus on healthcare technology. He co-founded NJTC Venture Fund and previously worked at Edison Venture Fund and Oracle. His investment experience includes healthcare payments, analytics and educational technology.

Venture affiliate, founder of Osprey Venture Partners and retired US Navy vice admiral. His experience includes global operations leadership at Estee Lauder, Compaq and Ryder and mentoring entrepreneurs. Military rank is biographical rather than part of his canonical personal name.

Venture affiliate with experience in healthcare and technology investing, operating support, software entrepreneurship and executive search. His career includes Acertitude and Battery Park and building and exiting technology businesses.

Venture affiliate and primary care physician specializing in clinical informatics. His work includes institutional clinical computing, electronic health records and decision support at academic healthcare organizations. BMP lists his name as Charles Safran despite a misspelled biography URL.

Venture affiliate with experience in clinical research and trial technology. His work at global contract research organizations includes innovation programs involving wearables, artificial intelligence, machine learning and electronic clinical outcome assessments.

Venture affiliate advising clinical research and medicine development organizations on digital innovation and patient engagement. He previously led clinical innovation at Pfizer and participated in the founding operations of TransCelerate Biopharma and clinical research ventures. Beaconcure appointed clinical-innovation adviser Craig Lipset to its strategic advisory board in June2023. Its primary announcement identifies him as a former Pfizer clinical-innovation head and adviser to biopharma, academic and technology organisations. He is not on its smaller2026 published advisory roster.

Venture affiliate focused on clinical research innovation, digital health and medicine development. She has worked across pharmaceutical consulting and industry, including founding a digital health consulting group at IQVIA. Her own Cytel biography identifies her as vice president for consulting strategy and operations.

Venture affiliate and physician with healthcare informatics, clinical data, analytics and life sciences experience. His work spans secondary uses of healthcare data, information technology policy and medical affairs. Historical leadership at the Multiple Myeloma Research Foundation is biographical rather than an independently verified current outside role.

Venture affiliate and physician working at the intersection of healthcare and technology. BMP spells his name George Matthew; his published DXC and professional membership profiles use George Mathew. His experience includes healthcare consulting, clinical technology and business development. This is the physician, distinct from the similarly named technology venture investor.

Venture affiliate and biopharmaceutical leader with experience in neuroscience, oncology, analgesia, infectious diseases, pediatric and orphan indications, drug-device products and digital therapeutics. Her career includes Bristol Myers Squibb, Otsuka and Click Therapeutics and development work on psychiatric medicines.

Venture affiliate and oncologist with clinical, healthcare operations and value-based oncology experience. His career includes leadership at The US Oncology Network, McKesson Specialty Health and academic cancer organizations. A named MAGI clinical research conference profile supplies his portrait.

Venture affiliate with expertise in pharmaceutical regulation, drug development and executive leadership. Her career includes senior regulatory roles at Sanofi, Reata Pharmaceuticals and Pfizer, with experience across innovative medicines, vaccines and other pharmaceutical products.

Venture affiliate, physician executive and scientist with leadership experience at academic hospitals in the United States and Canada. His work spans healthcare strategy, hospital management and life sciences advisory roles, including Sand Street Advisors. A separate Continuum Health Ventures directory supplies his verified portrait.

Venture affiliate and clinical development executive with pharmaceutical and contract research leadership experience. He previously led Health Decisions through growth and its 2021 acquisition. His experience includes clinical operations and oversight of international development programs.

Finance manager with more than 25 years of accounting and finance experience. Previously an accountant at the Education Collaborative of Massachusetts. She earned undergraduate and graduate management degrees at Trinity College Dublin.

Venture affiliate with experience in clinical development, operations and research technology. His career includes commercial clinical research work at Flatiron Health, strategy and innovation at Novartis, and leadership roles at IQVIA and Pfizer. Historical outside positions are not asserted as current employment.

Venture affiliate and co-founder of healthcare strategy consultancy Health Advances. She advises healthcare organizations on unmet clinical needs, business strategy and commercialization, drawing on decades of leadership across healthcare sectors. Her full published name is Paula Ness Speers.

Director of administration and investor relations who joined BMP in 2004. She supports limited partners and coordinates fundraising marketing. Previously she coordinated projects and fundraising logistics at alternative investment placement agent Atlantic Pacific Capital.

Senior associate, also known as Liz Callow, who joined BMP in 2011 after healthcare information technology marketing and business development work. She researches and evaluates health, wellness, technology and technology-enabled services investments and supports portfolio businesses.

Chief financial officer responsible for fund reporting, partnership taxation and limited partner communications. His accounting experience spans venture capital, healthcare, life sciences, diagnostics and technology, supporting businesses from seed financing through public offerings.

General partner of Boston Millennia Partners since the firm was founded in 1997. Previously a principal at its predecessor firm, assistant general counsel at Lifetime Corporation and a corporate attorney advising emerging growth businesses. His work combines investing, healthcare transactions and securities law.

Partner evaluating healthcare and logistics investments and supporting portfolio research and analytics. He worked with Odyssey Logistics during its sale process and joined BMP after a masters degree at the Fletcher School. Earlier experience includes consulting for US defense clients.

Co-founder and managing partner of Boston Millennia Partners. His experience includes co-founding a predecessor venture firm in 1982, strategic consulting at Braxton Associates and technology sales at Tymshare. He works with healthcare and technology businesses on growth and acquisitions.

Boston Millennia Partners (BMP) is a Boston venture and growth equity investment firm founded in 1997. It invests in healthcare and technology businesses, using thematic research and a buy-and-build approach to support growth and acquisitions. Its published directory includes seven management staff and 17 venture affiliates with clinical, research, technology and operating expertise; affiliates are not all full-time general partners. The Boston Millennia Founders Fund strategy, formed in 2014, supports early-stage healthcare and technology businesses, including clinical AI evidence company Atropos Health and healthcare analytics and drug discovery companies. The website reports a capital base exceeding USD700 million, which is not treated as a newly closed fund or an additive cash raise. Separate legal fund vehicles and dated actual securities sales are documented individually. The predecessor Boston Capital Ventures dates to 1982 and is not substituted for BMP’s 1997 founding. Some historical portfolio and outside job descriptions may remain on the published website; current outside employment is not inferred from those biographies.

John Ricks is identified by Sevaro Health as Senior Marketing Manager and its press contact in the September2025 financing and January2026 leadership announcements. An extended career biography and authentic personal portrait were not published in those sources; the dated press attribution does not establish membership in the current leadership directory.

Vascular neurologist appointed Sevaro Chief Medical Officer in August2023. Former University of California San Diego neurology professor and vascular-neurology fellowship director, with more than twelve years of teleneurology experience at appointment and published research in stroke and rehabilitation. The current2026 company leadership directory does not name him; this is a dated appointment attribution, not independent confirmation of continued current executive tenure.

Ajay Sharma is named as a director of Sevaro Health Inc in its June2025 SEC Form D and amendment, and its2023 filing. The filing provides no extended career biography or personally attributed portrait; no outside employer or personal investment ticket is inferred. Ajay Sharma is named as a manager of APA VP Management Company LLC, the manager of APA Venture Partners Fund I LP, in the fund’s2021 and2022 SEC filings and signed both notices. His Sevaro director affiliation is preserved separately. No unrelated Ajay Sharma portrait or additional employer is assumed from a name match.

Krishan Narula is named as an executive officer and director of Sevaro Health Inc in its2023 and June2025 SEC Form D filings. The specific executive title and career history are not published in these filings; he is distinct from founder Rajiv Narula.

Liz Learned Snyder is Butterfly Network's director of public relations and communications, identified in its current 2026 issuer announcements.

Michael (Mike) Noonen was appointed to Butterfly Network's board with a future effective date of October 9, 2026. As of the October 7 review he has not yet started that board term. He formerly led Swave Photonics and MixComm, held executive roles at GlobalFoundries and NXP, and co-founded semiconductor incubator Silicon Catalyst. He holds an electrical-engineering degree from Colorado State University.

Samhita Gaddam manages global-health program implementation at Butterfly Network, including its Gates Foundation-supported 1,000-probe initiative. Her background includes medical informatics and enterprise project management.

Taiba Zahir leads sales strategy and operational partnerships on Butterfly Network's Global Health team. She is a public-health professional and epidemiologist with experience in health systems and pandemic response.

Heather Harmon Donahoe develops partnerships, implementation projects and grant-funded programs on Butterfly Network's Global Health team. Her public-health background focuses on maternal and newborn health and healthcare delivery.

Sachita Shah is an emergency physician, educator and global-health ultrasound specialist on Butterfly Network's Global Health team. She leads clinical access and training initiatives and helped develop its Gates Foundation-supported 1,000-probe maternal-health program.

Caroll H. Neubauer joined Butterfly Network's board in May 2026. He is an executive advisor at Water Street Healthcare Partners and previously chaired and led B. Braun Medical in the United States, with service on its global management board. He studied law in Freiburg and holds a Georgetown University master of laws.

S. Louise Phanstiel chairs Butterfly Network's audit committee. She formerly led specialty products and finance functions at WellPoint and was an audit partner at Price Waterhouse. She is a certified public accountant with an accounting degree from Golden Gate University.

Elazer Edelman is a physician, biomedical engineer and Butterfly Network director. He holds professorships at MIT and Harvard Medical School and practices at Brigham and Women's Hospital. His research spans cardiovascular devices, biological delivery systems and translational medicine.

Larry Robbins founded Glenview Capital Management in2000 after working at Omega Advisors and Gleacher & Company. The current September2026 SEC filing lists his legal name Lawrence Michael Robbins and his role as chief investment officer; older issuer biographies calling him CEO are historical, with John Rodin named CEO from March2026. He holds economics and engineering degrees from the University of Pennsylvania. His existing Butterfly board affiliation and original portrait are preserved. Prior separately sourced company biography: Larry Robbins is Butterfly Network's lead independent director and founder, chief executive and portfolio manager of Glenview Capital Management. He founded Glenview in 2000 after working at Omega Advisors and Gleacher & Company. He graduated from the University of Pennsylvania with economics and engineering degrees.

David Horsley leads Butterfly Embedded innovation, product strategy, partnerships and commercialization. Appointed in March 2026, he is also a Northeastern University professor and nanosystems researcher. He co-founded Chirp Microsystems, acquired by TDK in 2018, and previously served as chief technology officer for emerging sensors at TDK InvenSense. He holds a Berkeley mechanical-engineering doctorate and is an IEEE and National Academy of Inventors fellow.

Arun Nagdev is an emergency physician and point-of-care ultrasound specialist appointed Butterfly Network's vice president and chief medical officer for POCUS in April 2026. His clinical and educational experience includes Highland Hospital and the University of California San Francisco, and he previously led clinical affairs at Exo.

Katie Gowryluk serves as Butterfly Network's chief of staff and leads talent acquisition. She previously worked in leadership recruiting at Daversa Partners and holds a bachelor's degree from Texas A&M University.

Paula LeClair leads Butterfly Network's home-care business. She previously built Healthy.io's United States operations as its first US employee and general manager. Her education includes Dartmouth healthcare-delivery science, a Bentley MBA and engineering and liberal-arts degrees from Notre Dame and Saint Anselm.

Ali is Partner and Co-Head of VC. She is responsible for investment strategy, sourcing, and portfolio management across early and growth-stage companies. Ali joined Artesian in 2017 and worked as an analyst for 3 years and portfolio manager for 4 years before her promotion to Partner in 2024. Ali was awarded Australian Clean Tech Investor of the Year in 2022, and was instrumental in the launch of Artesian's Female Leaders Fund in 2023. Ali completed a Bachelor of Commerce and Master of Business Law at the University of NSW.

Ananya is passionate about how technology can be harnessed to elevate underrepresented groups. Most recently, Ananya worked at Publicis Sapient as a management consultant, where she worked at the intersection of strategy and customer experience. Ananya is currently a Vice-Chair at the not-for-profit Women of Colour Australia. She fell in love with startups in her last year of university, where she founded a climate tech startup, and has now gone down the web3 rabbit hole to experiment with her own NFT collection. Ananya is extremely excited to be combining her two passions for tech startups and elevating women to support Artesian's Female Leaders Fund.

Andrew is the Managing Director of Boab AI Australia's first artificial intelligence scaleup investment program powered by Artesian. Prior to joining Boab/Artesian, Andrew was the Ventures Director at Deakin University helping to manage the university's portfolio of spinoff companies. Andrew was the founder of FinTech Melbourne, one of Australia's largest FinTech organisations and the Managing Director and Co-Founder of SproutX, Asia Pacific's first dedicated agtech accelerator and VC Fund. Andrew also spent 7 years at MLC where he was Risk and Analytics Manager. Andrew completed a Bachelor of Arts/Engineering (Hons) majoring in political science and software engineering from the University of Melbourne.

Asreen is a Senior Finance Manager and is responsible for overseeing Artesian’s financial and management reporting. Asreen joined Artesian in 2025 and has a Bachelor or Commerce (Accounting and Finance) from the University of Adelaide and is Chartered Accountant, with over 10 years’ experience working within the financial services sector. Prior to joining Artesian, Asreen was a Senior Operations Manager at Equity Trustees Limited (EQT) and a Senior Audit Manager at Ernst and Young (EY).

Bushra joined Artesian in November 2024 with 5 years of experience in Australian credit markets. Prior to joining Artesian, she worked at the Victorian Funds Management Corporation (VFMC) focusing on both internally and externally managed credit portfolios across public and private credit and at S&P Global Ratings as a securitisation ratings analyst. Whilst at VFMC, she was also responsible for driving ESG integration and sustainable bond analysis. Bushra has a Bachelor of Commerce with majors in Finance and Economics from the University of Melbourne.

Catherine is a Corporate and Fund Accountant at Artesian, supporting the firm's financial reporting and fund accounting operations.

Previously, Channing worked as Investment and Legal Manager at Youpeng Investment Management Co. Ltd with a focus on pharma and health investment. Channing has a Bachelor of International Business from Xiamen University TKK College and a Masters of Civil and Commercial Laws from Shanghai University of Finance and Economics.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists Chief Technology Officer, RIKAI Labs. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

David joined Artesian in 2013 and is the Head of Australian Fixed Income business. He is the Portfolio Manager of the Artesian Corporate Bond Fund and the Artesian Green & Sustainable Bond Fund. Prior to joining Artesian, David spent 9 years in the United Kingdom working for Deutsche Bank and RBS. David has a Master of Applied Finance from Kaplan (formerly Securities Institute of Australia). Whilst studying at the Securities Institute of Australia David was awarded with the Macquarie Bank Dux Award for being the top graduating student. Outside of work, David enjoys spending time with his 3 daughters and wife and hacking his way around the golf course.

David is currently a Venture Partner, focussed on assisting startups that have received investment from the South Australian Venture Capital Fund. He also sits on the Investment Committee for Galileo Ventures. David was previously the General Manager for Uber (Australia & NZ) after opening Uber’s operations in Australia in 2012. His first venture capital experience was as an Analyst at US VC firm Draper Fisher Jurvetson from 2008 to 2010. Prior to joining DFJ, David was a Senior Associate Consultant at Bain & Company working in Sydney and London. David has a B.Engineering (1st Class Honours) and a B.Finance from Adelaide University, and an MBA from Stanford University.

Felix is a Partner of Artesian Capital Management and runs Artesian’s Shanghai-based China venture capital business. Felix is responsible for later-stage VC analysis and investments for Artesian’s Australian and Asian fund and principal deals. Prior to joining Artesian in 2005, Felix worked in investment banking for 5 years with Banco Comercial Portuguese, Rand Merchant Bank, Morgan Stanley and CIBC in roles including alternative investments, quantitative research, equity research and derivatives trading/risk management. Felix has a BSc in Applied Math, Computer Science and Business from the University of Wisconsin, a Master of Business Administration from the Carlson School of Management, University of Minnesota and a Master in Finance from the London Business School.

Fiona is a Principal in the investment team and is responsible for the Artesian China VC Fund. She is based in Shanghai. Fiona joined Artesian in 2019 from Tronfund Asset Management where she was responsible for industry and financial due diligence, industry research and post-investment management. Prior to Tronfund, Fiona worked at UBS Securities as an Associate in the China auto team. Fiona has a Bachelor of Science (Financial Management) from Xiamen University and a Master of Science (Applied Finance) from Singapore Management University.

Gibson is a credit analyst based in Singapore. He is responsible for credit and interest rate research/trading across Artesian’s credit funds. Prior to joining Artesian in 2022, Gibson worked at a Singapore-based family office. Gibson holds a Bachelor of Science (Economics) from Singapore Management University. Outside of work, Gibson is an avid fan of Football, Formula 1 and Poker.

Gilles is a Partner at Artesian responsible for Artesian’s Venture Capital as a Service (VCaaS) business. VCaaS provides bespoke investment solutions to government organisations, corporates, industry groups and family offices. Artesian’s VCaaS partnerships include managing VC funds/investments for GrainCorp, Coca Cola EuroPacific Partners, and InvoCare. Gilles sits on the Investment Committees of Artesian VC funds. The VCaaS business leverages Artesian’s role as a VC investor/practitioner to provide partners access to the financial and strategic returns of the innovation ecosystem. VCaaS helps partners build early-stage startup ecosystems to help them access distributed R&D, build de-risked M&A pipeline and gain strategic context regarding threats/opportunities from the firehose of startup activity. Prior to joining Artesian, Gilles spent over 25 years in Financial Markets and International banking, where he held roles including CEO Asia Pacific, Deputy CEO Institutional & International Banking and Global Head of Markets for ANZ Banking Group and Crédit Suisse Bank. Gilles graduated with a Master of Computer Science Engineering degree (M.Sc) from ESME, Paris and has completed executive leadership degrees at Duke University and MIT Sloan School of Management.

Harry is a Sydney-based Associate in the Artesian VC investment team with focus across the AgTech portfolio. He holds a Bachelor of Engineering and Biotechnology from the University of Queensland and a PhD in AgTech, where he developed on-farm DNA testing tools. Harry founded a startup to commercialise his research before moving to London to lead ClimateTech commercialisation at University College London. Having grown up on a cattle farm and walked the path from research to founder, he brings a unique perspective to early-stage investing, combining scientific depth, operational experience, and a genuine connection to agriculture.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists Chief Executive Officer, Jaunt China. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Jeremy is CEO of Artesian which he co-founded in 2004. He established Artesian's VC business, now one of Australia's largest and most active early-stage venture capital managers. Prior to founding Artesian, Jeremy spent 15 years in fixed income and credit markets at SG Warburg and Lehman Brothers in New York and Hong Kong, and ANZ in Sydney where he was Global Head of Securities Trading and Institutional Sales.

John is a co-founder of Artesian and Partner, heading the firm's US operations from New York. He leads Artesian's global credit investment activities. Prior to Artesian, John was a Director at ANZ Banking Group where he traded credit and fixed income products across global markets.

Johny is a Director and Portfolio Manager at Artesian Capital Management in Singapore. He has been with Artesian since March 2010 primarily covering APAC credits. His role requires him to work closely with the firm's CIO/Managing Partners in areas of research, trading and investment idea generations for the APAC portion of the firm's global credit portfolio. In addition to portfolio management responsibilities, he is also responsible for maintaining good working relationships with debt issuers, sell-side traders and salespeople. Prior to joining Artesian, Johny was an analyst at The Royal Bank of Scotland's Singapore office. Johny graduated from Nanyang Technological University in Singapore in 2009 with a bachelor’s degree in Business majoring in Finance. He is also a CFA charter holder.

Jordan is a Principal in the VC investment team at Artesian, with primary responsibility for agrifood technology startups across the firm's venture funds.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists Executive Director & CFO, Times Internet Limited. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists CEO, Silk Road Telecommunication. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists Founder & CEO, CanCan Group. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Kirsten has joined Artesian with a focus on early stage tech investing in South Australia, through the SAVC Fund. Kirsten has a passion for high growth technology startups, and is a strong advocate for supporting women in technology and finance. Prior to joining Artesian, Kirsten spent time in San Francisco, working as an operator in strategic finance for a venture backed SaaS company. She also worked in technology banking, advising a portfolio of software, ecommerce, and online gaming clients on debt transactions up to $2bn. Before moving to the US, Kirsten worked in technology commercialisation for the University of Adelaide, and M&A with Big 4 firms KPMG and EY. Kirsten holds a Bachelor of Commerce from the University of Adelaide, and is a member of Chartered Accountants Australia & New Zealand, and the Australian Institute of Company Directors.

Kurt is a Managing Director based in NY and is a seasoned investment professional with a strong technology background. He is responsible for fixed income analysis and portfolio management as well as carbon research and measurement for North America. Since joining Artesian in 2005, Kurt has held a variety of roles, some in newly created positions and/or businesses. These roles include product development of the firm’s carbon impact product, analysis, trading, and technology. Prior to Artesian, Kurt designed and implemented full-stack enterprise trading applications for Barclays Capital. Kurt earned an MBA from the Leonard N. Stern School of Business at New York University with an emphasis in Entrepreneurship and Finance and a BSE in Computer Engineering from the University of Michigan. In his spare time, Kurt enjoys exploring the great outdoors and experimenting with sourdough bread recipes.

Luke is a Venture Partner supporting the Artesian VC business with a focus on select late-stage investments & board roles. Prior to joining Artesian in 2015 Luke was Managing Director UBS investment bank in New York, responsible for UBS America’s US Telecom, Media/Cable, and Technology trading business. Luke has a Bachelor of Commerce in Finance and Economics from the University of Melbourne. He has completed the Program for Leadership Development at Harvard University and is a Chartered Alternative Investment Analyst (CAIA).

Orbit’s financial-modeling expert in residence. His own Orbit biography says he runs Blockseed Ventures and previously led Emurgo and served as vice-chairman of the Cardano Foundation. Distinct from native ManmeetSingh, the PGV investor Manmeet Singh Bhasin.

Mark has almost 30 years capital markets experience, including work in investment banking, credit risk analysis, with international credit rating agency, Standards and Poors, and eight years in funds management, two as Director of Research, Asia Pacific, for an international investment management group and almost 20 years ESG research experience. In 2000, Mark founded the Sustainable Investment Research Institute, (SIRIS), Australia’s first dedicated, independent, specialist environmental, social and governance (ESG) research group. Mark holds bachelor degrees in law and economics and a Masters of Environmental Science from Monash University.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists Venture Partner, Orbit; Ostinato Capital LLC. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Mary Angelie joined Artesian in 2020 and works in the administration team on accounting and financial reporting across the Artesian group of companies and funds.

Matthew co-founded Artesian in 2004 and is the Chief Investment Officer of Artesian Capital Management. As well as being responsible for the firm’s global fixed income business, Matthew also sits on the investment committee of several Artesian VC Funds. With Matthew’s experience across both asset classes, it enables him to provide oversight into the operations of the global funds management business. Prior to Artesian, Matthew worked in investment banking at Macquarie Bank, HSBC and ANZ. He has a Bachelor of Economics from Monash University and a Graduate Diploma Financial Planning from Deakin University.

Mei is Head of Operations & Fund Administration, managing the daily operations of administering Artesian’s fixed income and venture capital funds which includes providing investor services to the fund’s limited partners and managing the funds’ investments. Mei joined Artesian as a fund accountant in 2006. In her 14 years with Artesian she has developed extensive knowledge and specialist skills across our fixed income and venture capital businesses. Mei has a Bachelor of Commerce and Bachelor of Information Systems, Accounting & Finance, and Business Information Systems from Melbourne University.

Since joining Artesian in 2012, Melody has gained broad investment experience and was promoted to Investment Director in 2019. Melody completed her Bachelor of Engineering at Shanghai JaioTong University majoring in Information Security at the School of Electronic Information and Electrical Engineering.

Nayoko is a Venture Partner and analyst based in Jakarta responsible for Artesian’s venture capital activities in Indonesia. Nayoko is also the co-founder and Managing Director of Algoritma, a data science education startup focused on building applicational data science skills using real world data and preparing students to be employable. Algoritma also does training for companies who have the need to develop data science capabilities internally. Nayoko was previously a Venture Partner at Plug and Play Indonesia and the Accelerator Director for the Plug and Play Tech Center. He completed a Bachelor of Arts (Economics & Commerce) at the University of British Columbia.

Nelson is a senior, hands-on operations leader with over 20 years of experience in investment operations, fund accounting, and cross-functional team leadership across Australia and Hong Kong. Recognised for balancing strategic oversight with day-to-day execution in small to mid-sized organisations, he has a proven ability to drive process improvements, enhance operational efficiency, and collaborate effectively with both internal and external stakeholders. Nelson joined Artesian in January 2026, bringing extensive experience in fund accounting and operations from Australian and international funds management companies. Nelson holds a Bachelor of Business (majoring in International Business and Finance) from Swinburne University of Technology and a Master of Business Systems from Monash University.

Nikolaos is an experienced multi-asset class portfolio manager and trader with over nineteen years of experience in fixed income. He has expertise in a broad range of credit products, rates and foreign exchange. Prior to joining Artesian, Nikolaos was Global Head of Commerzbank’s emerging markets credit trading team where he managed a substantial emerging markets portfolio and co-managed a banks and financials portfolio (Europe & USA) with consistent returns. He has also previously worked at investment banks including Nomura, Credit Agricole and Toronto Dominion Bank. His ability to manage sizable and complex trading portfolios won much recognition from counterparties, with whom he established strong relationships across the European and US trading hours. In his first two years at TD he was involved in trading and issuing Eurobonds in EM currencies, resulting in several IFR awards. Nikolaos began his career at Bank of America as an analyst and FX trader. He holds an MSc in Mathematical Trading and Finance from Cass Business School at the City University London.

Ollie is Artesian’s Finance Manager, Ollie is responsible for management & statutory reporting, budgeting & forecasting for Artesian. Ollie joined Artesian in 2025 and has 7 years of experience working as an external auditor in both big 4 and mid-tier accounting firms across the United Kingdom and Australia.

Richard is Head of Business Development involved in raising capital for all Artesian funds, building and maintaining relationships with our key investment partners including Institutions, Corporations, Family Offices and high net worth individuals. Richard is an accomplished and seasoned investment professional with significant global experience across a wide range of asset classes including corporate & government debt, listed & unlisted equities and early/growth stage venture capital. Richard has 39 years’ experience in financial markets. Before joining Artesian in 2013, Richard led Fixed Interest Sales & Credit Sales teams at HSBC & ANZ Global Markets. Richard began his career in stockbroking on the JSE in South Africa & then joined UAL Funds Management where his final role was, Portfolio Manager of Equities & Fixed Interest assets. Richard holds a Bachelor of Commerce in Marketing and Economics, University of Natal, is a Registered Representative of Sydney Futures Exchange & holds an AFMA dealer accreditation.

Robert is a Partner, joining Artesian in 2017. Based in Sydney, Robert leads Artesian's agrifood VC investment activities and is a portfolio manager for the GrainInnovate Fund and SproutX VC Fund. Artesian's agrifood VC strategy encompasses the broad agriculture and food value chain, including a focus on opportunities that have positive embedded climate and natural asset outcomes, and that have the potential to enhance global food security and sustainable agriculture. Prior to joining Artesian, Robert most recently worked as a manager within the agricultural investment team at Macquarie Infrastructure and Real Assets, a division within the asset management arm of the Macquarie Group. Robert graduated with a Bachelor of Arts / Bachelor of Commerce from the Australian National University.

Rohan is Partner and Co-Head of VC. He is responsible for investment strategy, sourcing, and portfolio management across early and growth-stage companies. Rohan joined Artesian in 2016 and worked as an analyst for 5 years and portfolio manager for 3 years before his promotion to Partner in 2024. Rohan previously worked at UBS and was also a Global Equities Trader specialising in special situation opportunities. Rohan holds a Bachelor of Commerce from Monash University with a Double Major in Accounting and Finance.

Rory joined Artesian in September 2019 as Director, Distribution. Prior to joining Artesian, Rory spent 15 years with Perpetual in various distribution focused roles, including three years in Dublin, as Managing Director of Perpetual International Investments, and prior to his departure in 2010 was the Acting Group Executive Global Equities. In 2011, Rory established his own Distribution firm, RMFS before joining Winston Capital Partners in 2013. Rory has a Bachelor of Economics and Business from Trinity College (Dublin) and a Graduate Diploma in Applied Finance and Investment.

Based permanently in WA, Sally leads Artesian’s investment activity in the state working closely with founders, co-investors and partners across government, corporates, universities, research institutes and family offices. Sally plays a central role in expanding Artesian’s Venture Capital as a Service (VCaaS) platform in Western Australia. Sally brings deep experience across strategic innovation, venture investing, M&A and emerging technologies, alongside a strong track record of operating in complex, real-economy sectors. Just as importantly, she has a genuine connection to Western Australia and a clear commitment to building long-term capability, not just deploying capital. Her three key responsibilities are to: (1) create durable financial and strategic value for WA-focused investors through partnership with ambitious founders and startups scaling globally from Western Australia, (2) partner with government, industry and research organisations to translate innovation into commercial outcomes, and (3) support Artesian’s growing cohort of WA–based investors across the Artesian Corporate Bond Fund and the Artesian Green & Sustainable Bond Fund.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists CEO and leadership team coach. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Shreen is a Senior Fund Accountant and Operations team member at Artesian, assisting with the daily administration of Artesian’s fixed income and venture capital funds.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists Chief Executive Officer, Pullpath. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Stephanie joined Artesian in 2023. As Principal, Stephanie leads the end-to-end venture investment process and strategy for companies in the SAVC Fund and Health Transformation vertical across Artesian. Stephanie has an extensive background in deep tech commercialisation, particularly in life sciences. Prior to joining Artesian, Stephanie worked as Director of Innovation & Translation at MTPConnect, and spent 5 years at Imperial College London as Director of Industry Partnerships & Commercialisation, Medicine and later as expert independent consultant. She also serves as consultant to TenU, hosted by the University of Cambridge. Stephanie brings experience from across the full commercialisation continuum including research, clinical development and technology translation, licensing, spinout formation and investment. Stephanie holds an MBA from the University of South Australia, is a Graduate of the Australian Institute of Company Directors (GAICD), a Certified Licensing Professional (CLP) and has tertiary qualifications in both Business and Biomedical Science. She also currently serves on the board for BiomeBank and Ferronova and previously served as Deputy Chair for the Cure4CF Foundation

Stuart joined Artesian in 2012 as a Managing Partner and equity owner and has been involved in all aspects of the venture capital business from capital raising to investing and external partnerships. Stuart’s current focus is the overall business strategy including management accountability, external partnerships and community development. Stuart has 25 years’ experience in finance across fixed income, commodities, forex and alternatives. Prior to Artesian Stuart worked at UBS for 15 years, most recently as Managing Director, Head of Asia Commodities in Hong Kong and previously Co-head of Global Hedge Fund distribution in London. Stuart has a Bachelor of Economics from Macquarie University, a Masters in Applied Finance from the University of Wollongong and is a Senior Fellow of the Financial Services Institute of Australia.

Tim is responsible for Artesian’s business in SE Asia and the Middle East and is closely involved with capital raising, new business development, strategy and the overall direction of the Artesian group. He was previously based in Artesian’s Shanghai office managing Artesian’s China VC Fund and has more than 25 years’ funds management and financial services experience both as a lawyer and senior executive. Tim has completed a Master of Banking and Financial Services Law from the University of Melbourne, a Bachelor of Laws from the University of Canterbury, NZ and a Bachelor of Science (Biology) from the University of Canterbury, NZ. Tim is a graduate of the Australian Institute of Company Directors and a member of the Australian Chamber of Commerce (Singapore).

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists SVP, New Digital Business and Innovation, Universal Music Group. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Ven joined Artesian in 2025 and works in Artesian's VC Investment Team as a Data Assistant to support the team across all VC portfolios and its investments. Venus graduated with a Bachelor of Science (industrial Engineering) from Ateno de Davao University, Philippines

Vicky is a Partner at Artesian and Head of Impact based in New York. Vicky joined Artesian’s VC business in 2015. She is focused on directing Artesian’s, and our investors’, capital, innovation and human endeavour towards positive social and environmental outcomes. Vicky sits on the Investment Committees of Artesian VC funds. Previously, she co-founded Zookal, a Silicon Valley venture-backed EdTech company and helped to scale the business 10x year-on-year as their Chief Operating Officer. Vicky has a Bachelor of Business (Economics & Management) and Bachelor of Arts of International Studies (Contemporary China) from the University of Technology, Sydney. Vicky was recognized as a Forbes Asia 30 under 30 recipient in April 2017.

Victoria Prowse is Director in the VC Sales and Relationship Management team. Victoria joined Artesian from Tomorrow Studio Ventures, and previously Rabobank, bringing with her a wealth of local and global knowledge in ecosystem building and innovation commercialisation. Having spent time developing programs and initiatives that bring food and agritech startups closer to funding and commercialisation, Victoria plays a pivotal role in supporting our agrifood initiatives across the region. Victoria completed a Bachelor, Applied Science at RMIT in Melbourne.

Published in Orbit’s combined Venture Partners and Experts in Residence section; the site also lists Chair, Tiger 21. The section does not distinguish individual venture partner versus expert status unless stated explicitly.

Jason Heim leads United States sales at Butterfly Network. He previously held senior sales leadership positions at Fujifilm Healthcare Americas and Siemens Healthineers and holds a bachelor's degree from Pennsylvania State University.

John Soto leads Butterfly Network's international business, including sales and strategic programs outside the United States. His earlier medical-device leadership roles include Vyaire Medical, KCI, AngioDynamics and Smith & Nephew.

Megan Carlson leads accounting and finance at Butterfly Network as chief accounting officer. She joined in 2021 and previously worked at Deloitte and Grant Thornton. She is a certified public accountant with accounting degrees from the University of North Carolina. Her interim chief financial officer assignment ended in December 2025.

Nicholas (Nick) Caezza is Butterfly Network's deputy general counsel and corporate secretary. He joined in 2021 and became corporate secretary in February 2024. He previously worked at Columbia Care and American Tower and holds a law degree from Suffolk University and a bachelor's degree from the University of Massachusetts Amherst.

Steve Cashman is Butterfly Network's executive vice president and chief business officer, overseeing business, product and corporate strategy functions. He previously led Caption Health through its acquisition by GE HealthCare and served as chief commercial officer at InTouch Health.

Victor Ku leads Butterfly Network's technology and product-development strategy. He joined in September 2025 after leading research, engineering and program management at Headwall Photonics. His earlier imaging and engineering experience includes Teledyne FLIR and EFI. He holds a doctorate in engineering science and electrical engineering from Oxford and an executive certificate from MIT.

John Doherty became Butterfly Network's executive vice president and chief financial officer in December 2025. His earlier finance and operating roles include Kaltura, Magic Leap, InterXion and Verizon. He studied economics at Stony Brook University.

Joseph DeVivo leads Butterfly Network as president, chief executive officer and board chair. Appointed in April 2023, he previously led Teladoc Health's hospital and health-system business and was chief executive of InTouch Health and AngioDynamics. He holds a business degree from the University of Richmond.

Butterfly Network, Inc. (NYSE: BFLY) is a US medical-technology company developing semiconductor-based portable ultrasound, clinical workflow software and AI-assisted imaging tools. Its Ultrasound-on-Chip platform powers the handheld whole-body iQ, iQ+ and iQ3 ultrasound systems. Compass AI supports enterprise workflow; the company states that Compass AI does not provide information for diagnostic or therapeutic decisions. Butterfly Garden supports ultrasound application development, while Butterfly Embedded licenses the semiconductor platform for partner-developed systems. Its neuroscience relevance includes ultrasound brain-imaging and brain-computer-interface research partnerships with Forest Neurotech, Aleph Neuro, Merge Labs and Bridge Neurotech; these commercial collaborations do not establish equity investments or neurological treatment approvals. Founded in 2011 by Jonathan M. Rothberg, the legacy operating company became BFLY Operations, Inc. when its February 12, 2021 combination with Longview Acquisition Corp. closed. The former SPAC renamed itself Butterfly Network, Inc. This profile represents the continuing business and public parent, with financing issuer scope qualified in each source. The current public team includes management, independent directors and its named Global Health operators. Restricted grants, historical preferred issuances, debt, completed SPAC proceeds and public equity are separately identified.

Quantum-Si Incorporated (Nasdaq: QSI) develops semiconductor-based single-molecule protein sequencing instruments and analytical software for proteomics research and drug discovery. The operating company was founded in 2013 by Jonathan M. Rothberg. Its technology combines advanced chemistry, proprietary semiconductor sensors and AI-enabled analysis to identify proteins, protein variants and modifications. Its commercial Platinum and Platinum Pro platforms are complemented by ProteoVue software; the Proteus platform is under development, with prototype results reported in 2026. Products are for research use only, not diagnostic use. The public Delaware corporation was originally incorporated as HighCape Capital Acquisition Corp on June 10, 2020 and acquired the operating predecessor on June 10, 2021; that merger renamed the public parent Quantum-Si Incorporated and the predecessor Q-SI Operations Inc. Merger share exchanges and enterprise valuations are distinguished from fresh cash financing. Current own directories publish four executives, ten directors and two scientific advisors, with one executive also serving on the board.

Alexander Huth, PhD, is a scientific advisor to Bridge Neurotech. The company’s current directory identifies him as an assistant professor of statistics and neuroscience at UC Berkeley, with expertise in computational models of language in the brain. His advisory affiliation is distinct from employment by Bridge.

Ashwin Ramayya, MD, PhD, is a scientific advisor to Bridge Neurotech. The company’s current directory identifies him as an assistant professor of neurosurgery at Stanford University, with expertise in functional neurosurgery and neuromodulation. His advisory affiliation is distinct from employment by Bridge.

Gianmarco Pinton, PhD, is a scientific advisor to Bridge Neurotech. The company’s current directory identifies him as a professor of biomedical engineering at UNC Chapel Hill and NC State, with expertise in ultrasound physics, imaging and therapy. His advisory affiliation is distinct from employment by Bridge.

Scott Sandell is executive chairman and chief investment officer of New Enterprise Associates (NEA). Its current biography says he previously served as CEO and managing general partner, joined in 1996, and led investments in technology businesses including Bloom Energy, Cloudflare, Robinhood, Salesforce, Tableau and Workday. He is a founding director of Venture Forward and an adjunct lecturer at Stanford. Bridge Neurotech’s October 2026 founder letter separately names Scott Sandell personally among its investors; that personal attribution does not establish an investment by NEA.

Bridge Neurotech Inc. is a Silicon Valley neurotechnology company founded in 2026 by Will Biederman to develop a non-invasive brain-computer interface. It is building a functional ultrasound imaging platform with AI-based neural decoding, initially focusing on transcranial sensing and real-time interpretation of brain activity without surgery or implanted hardware. Its observational research study in Redwood City enrolls healthy adults and adults with PEEK or Longeviti cranioplasty implants. The research configurations are investigational and are not FDA-cleared or approved. Its October 2026 founder’s letter reports USD13.5 million raised from General Catalyst, reMind Capital, Sunflower Capital, Scott Sandell and other investors, without disclosing the series label or exact closing day. On October6,2026 Bridge announced a multi-year licensing and R&D agreement using Butterfly Network’s Ultrasound-on-Chip technology; technology access, milestone payments and hardware purchases are commercial obligations rather than evidence of a Butterfly equity investment. Bridge is distinct from Forest Neurotech, which Biederman previously co-founded.

Will Biederman, PhD, is the founder and chief executive officer of Bridge Neurotech. During graduate research at UC Berkeley, he developed a neural-interface chip used in Neuralink’s first implants. He later worked at Google X and Verily, where he led development of the Dexcom G7 continuous glucose monitor in partnership with Dexcom. He co-founded Forest Neurotech and led engineering and development of its Forest 1 functional ultrasound imaging device before founding Bridge in 2026 to develop non-invasive ultrasound brain-computer interfaces.

Ruchir Shah is published by Sevaro as Director of Clinical Service Lines & Implementations. Board-certified vascular neurologist with a Duke University vascular-neurology fellowship. His published work encompasses stroke care, clinical trials, artificial intelligence, informatics and development of a comprehensive stroke center.

Steve Arbogast, DO, FAAN, is Medical Director of Product and Innovation at Sevaro Health. His current leadership affiliation links clinical neurology with the company’s virtual-care product development.

Stephanie Rubenstein, RN, SCRN, is Director of Healthcare Innovation and Partnerships at Sevaro Health, a physician-led virtual neurology company.

Lauren Voltz, RN, BSN, CEN, LEAN, is Assistant Vice President of Hospital Partnerships at Sevaro Health, supporting the company’s hospital-facing virtual neurology services.

Sam K. Saha, MD, is Vice President of Medical Operations and Technology at Sevaro Health. The company’s physician-careers page also publishes his work on clinician support and collaboration in its virtual neurology services.

Melanie J. Winningham, MD, is Vice President of Clinical Strategy and Partnerships at Sevaro Health. Her published physician-leadership work focuses on expanding neurological-care access and building collaborative virtual-care systems for hospitals, patients and clinicians.

Bethany Brandt, BSN, RN, SCRN, is Vice President of Clinical Operations and Quality at Sevaro Health, the physician-led virtual neurology provider.

Becky Mallon, RN, BSN, SCRN, is Senior Vice President of Client Success and Physician Engagement at Sevaro Health. Her current public leadership affiliation covers hospital-client relationships and physician engagement in virtual neurology.

Vineet Agrawal is published by Sevaro as SVP & Head of Growth. Healthcare technology growth executive with eleven years at Penumbra, including global stroke and neurovascular commercial leadership. The current page also uses Head of Growth on a duplicated corporate card; the SVP prefix is explicitly published on its other card.

Chethan Sathya is published by Sevaro as Chief Physician Executive. Physician executive whose published clinical and public-health work includes convening the National Specialty Care Access Coalition with Raj Narula in February2026 to improve specialist access in underserved communities. Northwell pediatric trauma surgeon and director of its gun-violence-prevention center, with an academic appointment at the Zucker School of Medicine. Trained in Toronto and Northwestern pediatric surgery. This verified concurrent Northwell affiliation preserves his separate existing Sevaro biography and portrait. Published Northwell affiliation: Trauma Surgeon; Director, Center for Gun Violence Prevention.

Kirtana Vedire, DMD, is Chief Operating Officer of Sevaro Health, a physician-led provider of virtual neurology and specialty-care services.

Carl Dugart is published by Sevaro as CTO. Healthcare technology executive with experience scaling engineering teams and EMR-integrated clinical platforms. Previously led technology initiatives at Medically Home.

Jason Bond is published by Sevaro as CFO & SVP of Strategy. Healthcare finance and strategy executive with prior leadership experience at Mount Sinai, Yale New Haven Health and CityMD, including mergers and acquisitions and value-based care.

Rajiv Narula is published by Sevaro as Founder & CEO. Physician founder, also published as Raj Narula. Former Sevaro Chief Medical Officer and Director of Teleneuroscience at Cooper University Hospital; the company announced his CEO appointment on August29,2023.

US digital-health company developing behavioral health software for women across pregnancy, postpartum care, fertility and menopause. Its connected-care platform links assessments and digital programs with providers, health plans and insurers. MamaLift Plus is an eight-week prescription digital therapeutic for mild-to-moderate postpartum depression in adults aged 22 and older, used alongside clinician-managed outpatient care; the FDA cleared this Class II device in April 2024. Its wider platform includes personalized behavioral support and monitoring.

Audiologist, hearing therapist and published Oto content contributor; listed on the company’s specialist program page, without inferring a corporate executive appointment.

Former military doctor who co-founded Oto to improve access to support for people experiencing tinnitus.

Doctor with eight years of Royal Navy experience who co-founded Oto following his own experience of tinnitus.

Gregory Echt is identified as a director of Senseye, Inc., the Austin neurotechnology company, in its October7,2025 SECFormD amendment. Sources do not establish a current2026 title or authentic publicportrait here.

ENT consultant and hearing researcher whose expertise helped shape Oto’s program; Hunterian Professor is an external academic distinction, not a corporate executive role.

Nordic Foodtech VC is a Helsinki-based venture capital manager investing in pre-seed and seed companies applying scientific discovery and engineering to food and agriculture. Its investments include precision fermentation, alternative proteins and fats, aquaculture, agricultural sensing and nutrient recycling. Established in 2019, it invests across Europe with an emphasis on the Nordic and Baltic countries, including university and research spin-outs, and reserves capital for follow-on financing. Its team operates from Helsinki and Copenhagen.

Kerry Ressler is Medical Advisory Board Member at Senseye, Inc., the Austin mental-health diagnostics company, according to its official team directory reviewed October 7, 2026.

Steven Berkowitz is Medical Advisory Board Member at Senseye, Inc., the Austin mental-health diagnostics company, according to its official team directory reviewed October 7, 2026.

Barbara Rothbaum is Medical Advisory Board Member at Senseye, Inc., the Austin mental-health diagnostics company, according to its official team directory reviewed October 7, 2026.

Caitlin Limonciello is Director, Research at Senseye, Inc., the Austin mental-health diagnostics company, according to its official team directory reviewed October 7, 2026.

Brad Strasser is VP, Clinical, Quality & Regulatory at Senseye, Inc., the Austin mental-health diagnostics company, according to its official team directory reviewed October 7, 2026.

David Durrant is SVP, Development at Senseye, Inc., the Austin mental-health diagnostics company, according to its official team directory reviewed October 7, 2026.

Allison Fabian is SVP, Strategy and Operations at Senseye, Inc., the Austin mental-health diagnostics company, according to its official team directory reviewed October 7, 2026.

David Zakariaie is CEO & Founder at Senseye, Inc., the Austin mental-health diagnostics company, according to its official team directory reviewed October 7, 2026.

Senseye, Inc. is an Austin-based neurotechnology company developing an investigational smartphone platform for objective mental health assessment, initially focused on PTSD. Its software uses computer vision, machine learning and ocular biomarkers such as pupil dynamics and eye movements. The company states that its device is for investigational use and its performance characteristics have not been established; clinical research and planned indications do not establish FDA marketing approval. Founder and CEO David Zakariaie leads the company. The current public directory names five leadership professionals and four medical advisers. SEC filings identify this Delaware corporation as CIK1656387, organized in2015, initially inLosAngeles and laterAustin. Topcon Healthcare announced a strategic investment inSeptember2025, and Capital Factory identifies it as a Texas FundII holding. It is separate from the industrial predictive-maintenance company Senseye at senseye.io; none of the industrial company funding is assigned here.

BlueBean develops a virtual-card-first spend and expense-management platform for business purchases. Its browser extension and mobile app let employees request and use approved virtual cards at online or in-store checkout, while finance and procurement teams enforce supplier, budget and policy controls. AI-supported checks, receipt capture, real-time transaction visibility and automated accounting reduce manual purchase approvals and expense reconciliation. The software works with existing corporate card programmes and banking relationships, helping companies control spending without installing a traditional procurement system.

Lumeus.ai develops security software for AI coding agents, Model Context Protocol tools and developer access to enterprise infrastructure. Its gateway observes agent interactions, enforces access policies, scans tool requests and responses, and uses temporary credentials to limit standing access. Originally built around zero-trust network visibility, it expanded into governance at the IDE, command-line and code-generation layers. Fiddler AI acquired Lumeus in April 2026 to extend its AI Control Plane from runtime monitoring into the creation and execution of coding-agent workflows.

Navidence develops AI-native software and professional services that help healthcare and life sciences researchers design studies and determine which real-world health data is suitable for them. Its platform creates and curates Computable Operational Definitions, standardized human- and computer-readable descriptions of diseases, treatments, outcomes and other study elements. Researchers reuse these definitions to align study design, evaluate data suitability and make analyses more consistent, transparent and reproducible across clinical research studies and trials.

Woodway Assurance is a Canadian privacy technology company developing EviData, subscription software that assesses whether de-identified, anonymized and synthetic datasets can be used and shared responsibly. Its AI-enabled workflow measures re-identification risk in structured data and unstructured text, recommends and performs privacy-preserving transformations, and produces auditable evidence for privacy and data governance teams. The platform runs inside the customer’s environment and supports artificial intelligence, analytics and health research. Woodway spun out of the Electronic Health Information Laboratory at the CHEO Research Institute.

Real-world data and evidence specialist with former healthcare data strategy experience at Roche/Genentech and real-world data services experience at Parexel.

Pharmaceutical development and clinical research services executive with former roles at IQVIA, Parexel and inVentiv Health.

Communications and privacy professional with former experience at Canada’s federal privacy regulator.

Medical informatics specialist and former scientific data technology executive at Parexel.

Design and UX leader who previously worked at Koble and Coupa, with experience in enterprise branding and digital products.

Procurement entrepreneur who founded Koble, later acquired by Coupa, and previously led SaaS business Sievo.

Former Koble and Coupa engineer specialising in supplier intelligence, matching algorithms and machine learning; studied electrical engineering and computer science at MIT.

Technology entrepreneur and former bluArc Communications chief executive supporting enterprise adoption of privacy risk mitigation.

Medical AI researcher and University of Ottawa professor who leads the Electronic Health Information Laboratory at the CHEO Research Institute, the source of Woodway’s privacy technology.

University of Ottawa researcher specializing in privacy-enhancing technologies, with clinical training in Germany.

Technical leader developing scalable healthcare, data science and privacy solutions, with former leadership experience at Datavant and Replica Analytics.

Health and data-law strategist working on de-identification, shared data platforms, artificial intelligence and health research.

Clinical research services and consulting executive; formerly led data-driven research at IQVIA and strategic operations at Syneos Health.

Research and bioinformatics executive with former clinical informatics leadership experience at Health Catalyst.

Enterprise software architect and former Koble CTO; previously led integrations at Sievo and worked as chief architect at Basware.

Infrastructure, security and software engineering leader whose public professional profile lists Lumeus; exact current title is hidden.

Co-founded Lumeus and led its evolution from machine-learning network visibility to secure developer access and coding-agent security.

Co-founded Lumeus with Satish Veerapuneni; primary manager announcement verifies founder identity. Widely published CTO title is not exposed by the current accessible primary profile.

Finance executive with experience supporting technology companies through growth and acquisitions.

Built production AI infrastructure and the Lumeus MCP gateway, including security inspection and cross-platform deployments. Subsequently publicly announced he was seeking new engineering opportunities.

Venture fellow at Audere Capital. Published background includes an associate role at Segal Ventures and seven years of UST/MBS trading at Nomura. Outside role career context not proof of cash attribution.

Venture fellow at Audere Capital. Its directory describes work for the Atlantic Council empowerME initiative and prior international-policy organizations including the Washington Institute, Religious Freedom Institute and Iraq Mission to the United Nations. Other employment tenure is not independently confirmed.

Associate at Audere Capital. Naval Academy graduate and former P-8A naval flight officer, with published experience at Shield AI and No One Left Behind.2020Tillman Scholar; the directory also describes Harvard public-policy and business study without independent completion-date inference.

Senior advisor at Audere Capital. Published biography describes Bellnote Partners climate-technology investing and cofounding/leading Lightship Works, integrating field data, sensors and asset tracking. External portfolio valuations are context, not Audere holdings or fund assets.

Senior advisor at Audere Capital and retired diplomat. Her published biography describes thirty years at the State Department, ambassador to the African Union/UN Economic Commission for Africa and Atlantic Cooperation leadership. It also names Busara Advisors, American University and ForSea Invest affiliations; Harvard BA and Cambridge MPhil.

Senior advisor at Audere Capital. Published career experience includes Altana federal supply-chain technology, CIA analysis, EUCOM, defense intelligence, McKinsey and Fulbright study in Poland/Ukraine. Outside employer roles are contextual rather than independently confirmed concurrent employment.

Retired rear admiral and Audere Capital senior advisor, published as Wyman Howard. A former SEAL officer with Naval Special Warfare Command and Special Operations Command Central leadership, intelligence and counterterrorism policy experience. His biography includes MIT artificial-intelligence and business-strategy training.

Retired brigadier general and Audere Capital senior advisor. Published experience includes Air Force international affairs, Iraq defense attaché service, Edwards Air Force Base/412th Test Wing command and Defense Department special-access programs.

Senior advisor at Audere Capital with published experience at Brunswick Group, Burson-Marsteller, PBS, the White House and Discovery. Communications and strategy background is historical/career context; no external current board or cash attribution inferred.

Retired lieutenant general and Audere Capital senior advisor. Published experience includes leading the Joint Improvised Explosive Device Defeat Organization, US/NATO Iraq command and Fort Benning, alongside SAAB governance experience.

Senior advisor at Audere Capital. Published background includes US presidential homeland-security and counterterrorism advisory work, National Security Council and Justice Department leadership, plus Council on Foreign Relations, Chubb and Freeport-McMoRan governance experience. These are career-context statements rather than inferred concurrent executive employment.

Climate-technology investor and Audere Capital venture partner, working across materials, energy, water, waste, agriculture and supply chains. Published background includes374Water founding-team/government work, Lavit cofounding and Farm to Fork, Sustainable Ocean Alliance and Nexus advisory affiliations. Distinct from the UT Southwestern biochemist and Nura Bio scientific founder with the same name.

Venture partner at Audere Capital. Published career background includes HQ Digital operations leadership, Figure Technologies founding-team experience and ten years at Goldman Sachs. Outside employer AUM is not Audere capital.

Venture partner at Audere Capital with published experience at Aalyria, US Air Force emerging-technology policy and the Department of Defense AI Workforce Subcommittee. Listed as a Presidential Leadership Scholar. Outside career positions are biography context, not separately verified current employers.

Venture partner at Audere Capital. Its biography describes cofounding ICON, advanced-materials and3D-printing technology, founding Saturn Five and TreeHouse, and Council on Foreign Relations membership. Company valuations are contextual historical claims, not Audere fund sizes.

Co-founder and general partner of Audere Capital. Previously general partner at Fin Capital and CFO/partner at SymphonyAI; founding CFO and early board member at ConcertAI. His investing and operating experience spans AI and financial technology. UVA MBA and William & Mary BBA. SEC filings confirm fund GP leadership; prior employer assets and past investments are separate from Audere holdings.

Co-founder and general partner of Audere Capital, specializing in advanced technology and global-security investment. Previously investment principal at Rose Park Advisors and cofounder/GP of GCVC. Her published background includes AI/ML, robotics, computational data and commercial innovation, Wharton MBA and UC Santa Barbara undergraduate studies. SEC FundI filing identifies Margaret Sprenger as managing member of its GP.

Audere Capital is a US advanced-technology venture investment firm and innovation platform co-founded by Maggie Sprenger and Peter Ackerson in2023. Its stated strategy connects investment, policy and operating expertise to artificial intelligence, autonomy, defense, healthcare, advanced materials and infrastructure. Its own website identifies Audere Capital LLC; SEC filings independently identify Audere Capital, LLC as manager of Audere Capital SPV11 LLC and the founders as principals of the Delaware Audere Capital FundI LP general partner. Its own company page lists New York City headquarters, while fund filings show a Ridgefield, Connecticut administrative address. The published directory includes two general partners, five venture partners, eight senior advisors, one associate and two venture fellows. AI/healthcare relevance includes Atropos Health’s primary-confirmed September2023 strategic financing, BioPhy clinical-trial/drug-development AI and a published Heimdall genomic-AI portfolio entry. Roles in prior firms and their historical portfolio successes are not automatically Audere investments. This exact audere.capital US firm is distinct from Dubai-regulated Audere Capital Partners Limited and audere-ventures.com. The FundI April2025 amendment reports4.61MUSD sold toward a100MUSD ongoing offering, not a100M closed fund; SPV11 August2025 filing reports first sale yet to occur. Both legal vehicles are recorded without invented final close sizes or dates.

Melina Mathur, Ph.D., is publicly associated with Asset Management Ventures in its own LinkedIn employee directory. The firm’s own archived January2022 team page identifies her as an Advisor. Her exact current title and appointment dates are not established by the available current primary sources; the historical advisory title is not assumed to prove current full-time employment.

MicroPort Scientific Corporation is a Shanghai-based medical-device group listed on the Hong Kong Stock Exchange under stock code 00853 and incorporated in the Cayman Islands. Its operating business began in Shanghai in 1998. The group develops and markets cardiovascular, orthopedic, cardiac-rhythm, endovascular, neurovascular and structural-heart devices, medical imaging and surgical robotics. Its published leadership includes a function responsible for AI manufacturing and global supply chains. Strategic investments include Promaxo’s portable MRI technology and NDR Medical’s AI-assisted needle-targeting robotics. The listed parent is distinct from separately listed and operated companies such as MicroPort NeuroScientific, MicroPort MedBot, MicroPort CardioFlow and MicroPort Endovascular. Jonathan W Chen is the current rotating chief executive; founder Zhaohua Chang chairs the board and serves as chief scientific officer. The parent’s financing history includes its 2010 IPO, equity placements, convertible bonds and drawn corporate loans. Fundraising by subsidiaries and cumulative group financing totals are separate from parent-company proceeds.

Benoit Clinchamps oversees MicroPort Scientific’s overseas operations. He previously headed the group’s cardiac-rhythm-management business and held medical-technology roles at LivaNova, Sorin and GE Healthcare. His engineering education was at ICAM in France.

Brian Yale Chang is MicroPort Scientific’s chief medical officer and also heads MicroPort Scientific America. He is a physician and engineer whose work includes cardiac-support technologies. His education spans Carnegie Mellon, MIT and Harvard Medical School, with medical residency at Massachusetts General Hospital.

Chunyang Shao is an independent director of MicroPort Scientific and a JunHe partner. His legal work includes corporate transactions, foreign investment, securities and project finance. He studied law at East China University of Political Science and Law and qualified to practice in China in 1988.

Feng Gu is a MicroPort Scientific non-executive director appointed in September 2025. His experience spans financial management, industrial investment and corporate governance. His published career includes finance and investment leadership at Shanghai Industrial Investment.

Greg Holman oversees MicroPort Scientific’s global commercial strategy. His earlier career included senior roles at Boston Scientific and Stryker and an operating-partner appointment at LYFE Capital. He earned an MBA at Washington University in St. Louis and an undergraduate degree at Wittenberg University.

Guoen Liu is an independent director of MicroPort Scientific and a health economist. His academic work includes Peking University’s global-health and development institute and its National School of Development. His training includes mathematics, statistics, economics and health economics.

Guoming Chen oversees project investment management and technology development at MicroPort Scientific. Since joining in 2010, his work has included valve development, project management and manufacturing processes, including the VitaFlow transcatheter-valve program.

He Li is MicroPort Scientific’s board secretary and leads securities and legal affairs. She joined the group in May 2016. Her operating board-secretary role is distinct from the listed issuer’s separate company-secretary appointment.

Hongbin Sun leads finance at MicroPort Scientific. His earlier work included finance and general management at Otsuka China and accounting at KPMG Shanghai. He studied economics at Shanghai Jiao Tong University and holds Chinese CPA and CFA credentials.

Jie Zhang directs MicroPort Scientific’s Greater China technology function. He joined the company in 2007 and has worked on its medical-device research. His published professional experience includes technical leadership in Shanghai and postgraduate mentorship.

Jing Huang joined MicroPort Scientific’s board as a non-executive director in August 2026. Her career spans investment management and human resources in Shanghai’s Pudong and Zhangjiang development organizations. She studied management at the University of Science and Technology of China and Shanghai University.

Jonathan H. Chou is an independent director of MicroPort Scientific. His finance career includes UTAC and Kulicke & Soffa, with earlier multinational industrial and technology roles. He holds an MBA from Duke and an economics degree from the University at Buffalo.

Jonathan W Chen leads MicroPort Scientific as rotating chief executive. His earlier MicroPort responsibilities covered overseas operations and investor relations. Before MicroPort, he worked in business development at Angiotech and in life-sciences investment banking. He studied economics and biological sciences at Stanford. This executive is distinct from the Ammobia chemical engineer Jonathan Chen.

Lei Jiang directs MicroPort Scientific’s Greater China sales and marketing. His career includes pharmaceutical and vascular-device work at Mitsubishi Chemical and Abbott, followed by coronary-device marketing at MicroPort.

Qing Hui leads organizational capability at MicroPort Scientific. She joined in July 2019 after human-resources leadership work at Boston Scientific. Her company remit concerns organizational development at headquarters.

Tianbai Yu appears in MicroPort Scientific’s global leadership directory through his subsidiary responsibilities: leading MicroPort Orthopedics China and the orthopedics business’s global supply chain. He joined the group in 2015 and previously led Suzhou MicroPort OrthoRecon operations.

Weiqin Sun has served as a MicroPort Scientific non-executive director since August 2023. Her professional background includes Zhangjiang venture-capital, incubation and investment-service management. She studied Chinese language and literature at Shanghai University and earned an MBA at Fudan.

Yeung Siu Lam is the company secretary and an authorized representative of MicroPort Scientific, appointed on March 31, 2026 according to its latest annual report. She holds ACG and HKACG professional designations. Her listed-issuer company-secretary appointment is distinct from He Li’s operating board-secretary and legal-management role.

Yimin Xu oversees MicroPort Scientific’s regulatory affairs and infrastructure. His earlier MicroPort responsibilities included quality and regulatory management. He joined the company in 2000 following project-management work at Shanghai Zhangjiang.

Yingyao Chen joined MicroPort Scientific’s board as an independent director in June 2026. He specializes in health-technology assessment and hospital management and is a professor and vice dean at Fudan University’s School of Public Health.

Yiyun Que oversees AI manufacturing and the global supply chain at MicroPort Scientific. His earlier company appointments covered coronary-device manufacturing and engineering. The company describes more than twenty years of medical-device experience.

Zhaohua Chang founded the MicroPort operating business in Shanghai in 1998 and now chairs MicroPort Scientific’s board and serves as chief scientific officer. His earlier medical-device work included Endocare and Cryomedical Sciences. He studied refrigeration and cryogenic engineering and earned a biological-sciences doctorate at SUNY Binghamton.

Feldan Therapeutics board member and a managing director at Genesys Capital, according to the company’s board biography and September2024 financing announcement. His background includes life-science venture investment and biotechnology board service. Feldan identifies an MBA qualification. Managing director of Genesys Capital. Joined in2002 and became partner in2007. His current manager biography describes board work including Feldan, Enspire DBS Therapy, Giiant and Veralox. Earlier worked in genetic diagnostics at Mount Sinai’s Samuel Lunenfeld Research Institute; holds Queen’s biology and Rotman MBA qualifications.

Board member of Feldan Therapeutics with pharmaceutical commercial leadership and consulting experience. Her published company biography describes executive work at Allergan and Kythera and board service in biotechnology. Feldan identifies an MBA qualification.

Feldan Therapeutics board member appointed in January2025. Previously chief medical officer and global head of development at Allergan, with more than three decades of clinical and non-clinical pharmaceutical-development experience according to the company. Feldan identifies PhD and MD qualifications.

Board member of Feldan Therapeutics. Her official biography describes extensive drug discovery and development experience and leadership in Canadian biotechnology. Feldan identifies a master’s qualification; the company’s current board directory establishes her affiliation.

Annie Boucher is named by Feldan Therapeutics as CLINICAL TRIAL ASSISTANT. The company directory lists Annie Boucher, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Chair of Feldan Therapeutics. The company describes his experience leading pharmaceutical development and serving on public and private company boards in several countries. His education includes an analytical-chemistry doctorate and chemistry master’s from the University of Massachusetts Amherst and a research fellowship at EPFL.

Félix Bégin is named by Feldan Therapeutics as MASTER'S STUDENT. The company directory lists Félix Bégin, BSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Flora Peillard Fiorente is named by Feldan Therapeutics as STRATEGIC DEVELOPMENT SPECIALIST. The company directory lists Flora Peillard Fiorente, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Jonathan Roger is named by Feldan Therapeutics as CLINICAL STUDY MANAGER. The company directory lists Jonathan Roger, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Nayeli Esparza is named by Feldan Therapeutics as POSTDOCTORAL FELLOW. The company directory lists Nayeli Esparza, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Gaëlle Bourriquen is named by Feldan Therapeutics as RESEARCH SPECIALIST II. The company directory lists Gaëlle Bourriquen, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Jean-Pascal Lepetit-Stoffaes is named by Feldan Therapeutics as Director - Strategic Development. The company directory lists Jean-Pascal Lepetit-Stoffaes, PhD, Eng; The current official directory establishes this affiliation; appointment date is undisclosed.

Marie-Michèle Labrecque is named by Feldan Therapeutics as ASSOCIATE CLINICAL STUDY MANAGER. The company directory lists Marie-Michèle Labrecque, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Alain Houde is named by Feldan Therapeutics as LABORATORY TECHNICIAN. The company directory lists Alain Houde, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Alex-Anne Allaire is named by Feldan Therapeutics as COMMUNICATIONS & ADMINISTRATION ASSOCIATE. The company directory lists Alex-Anne Allaire; The current official directory establishes this affiliation; appointment date is undisclosed.

Olympe Garnier--Leymonerie is named by Feldan Therapeutics as PHD STUDENT. The company directory lists Olympe Garnier--Leymonerie, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Catherine Lippé is named by Feldan Therapeutics as VP - Clinical Development. The company directory lists Catherine Lippé, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Julie Philippe is named by Feldan Therapeutics as ADMINISTRATIVE ASSISTANT. The company directory lists Julie Philippe; The current official directory establishes this affiliation; appointment date is undisclosed.

Mia Pelletier is named by Feldan Therapeutics as PHD STUDENT. The company directory lists Mia Pelletier, BSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Christine Hurley is named by Feldan Therapeutics as Director - Quality Assurance & Compliance. The company directory lists Christine Hurley, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Luis Sorroza is named by Feldan Therapeutics as RESEARCH SPECIALIST II. The company directory lists Luis Sorroza, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Mario Harvey is named by Feldan Therapeutics as SENIOR RESEARCH SPECIALIST. The company directory lists Mario Harvey, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

David Guay is named by Feldan Therapeutics as VP - INNOVATION & TECHNOLOGY. The company directory lists David Guay, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Imen Arbi is named by Feldan Therapeutics as RESEARCH SPECIALIST I. The company directory lists Imen Arbi, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Janick Sirois-Fraser is named by Feldan Therapeutics as Financing & Business Development Associate. The company directory lists Janick Sirois-Fraser, BSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Maxime Hervault is named by Feldan Therapeutics as RESEARCH SPECIALIST II. The company directory lists Maxime Hervault, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Nadine Brahiti is named by Feldan Therapeutics as PROJECT MANAGER - DRUG DELIVERY TECHNOLOGIES. The company directory lists Nadine Brahiti, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Stéphanie Levesque is named by Feldan Therapeutics as Director - Corporate Governance & Communications. The company directory lists Stéphanie Levesque, BSc, MBA; The current official directory establishes this affiliation; appointment date is undisclosed.

Kelly Tanguay is named by Feldan Therapeutics as Research Specialist I. The company directory lists Kelly Tanguay, BSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Vincent Ménard is named by Feldan Therapeutics as Chief Financial Officer (CFO). The company directory lists Vincent Ménard, PhD, MBA, CFA; The current official directory establishes this affiliation; appointment date is undisclosed.

Vanessa Théberge is named by Feldan Therapeutics as PROJECT MANAGER - DRUG DISCOVERY. The company directory lists Vanessa Théberge, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Isabelle Deschênes is named by Feldan Therapeutics as Accounting and Logistic Coordinator. The company directory lists Isabelle Deschênes; The current official directory establishes this affiliation; appointment date is undisclosed.

Nancy Messier is named by Feldan Therapeutics as SENIOR VP - DRUG DISCOVERY. The company directory lists Nancy Messier, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Pierre-Alain Moisset is named by Feldan Therapeutics as DIRECTOR - DRUG DEVELOPMENT. The company directory lists Pierre-Alain Moisset, PhD, MBA; The current official directory establishes this affiliation; appointment date is undisclosed.

Anne-Marie Duperré is named by Feldan Therapeutics as RESEARCH SPECIALIST III. The company directory lists Anne-Marie Duperré, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

CEO and co-founder of Feldan Therapeutics. His official biography describes co-founding the company while completing a chemical-engineering doctorate and leading its transition from biological-reagent production and distribution to intracellular delivery technology and investigational therapeutics. He is also listed as a Feldan and Bio-Québec board member.

Meriem Benchabane is named by Feldan Therapeutics as VP - STRATEGIC DEVELOPMENT & OPERATIONS. The company directory lists Meriem Benchabane, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Al Halifa Soultan is named by Feldan Therapeutics as Director R&D – Drug Delivery Technologies. The company directory lists Al Halifa Soultan, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Anna Xue Cheng is named by Feldan Therapeutics as Director R&D – Pulmonary Drug Delivery. The company directory lists Anna Xue Cheng, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Maud Auger is named by Feldan Therapeutics as RESEARCH SPECIALIST II. The company directory lists Maud Auger, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Feldan Therapeutics is the operating name of Feldan Bio Inc., a clinical-stage biotechnology company based in Québec City, Canada. Its GLEIF legal-entity record identifies Québec registration 1164440852 and incorporation on 15 May 2007. The company develops intracellular delivery technologies and investigational treatments for skin and lung diseases. Its proprietary Feldan Shuttle is a peptide-based platform designed to deliver therapeutic cargo, including antisense oligonucleotides, into cells and overcome endosomal entrapment. This drug-delivery platform makes Feldan relevant to deep technology and biotechnology. The current company directory describes FLD-103 as an investigational intralesional, non-surgical treatment for basal cell carcinoma in a Phase 1 trial at sites in the United States and Australia; its March 2026 project announcement refers to the program as Phase 1/2a. The Australian trial is overseen by wholly owned Feldan Australia Pty Ltd. FLD-201 is an inhaled investigational therapy for mucus-driven respiratory diseases, including non-cystic fibrosis bronchiectasis and chronic bronchitis, in preclinical development. Separate collaborations investigate pulmonary delivery, genome-editing cargo and integration of the Shuttle with lipid nanoparticles for mRNA delivery. These descriptions concern investigational programs and company-reported delivery capabilities. François-Thomas Michaud is CEO and co-founder. The current public directory names 35 staff members and seven board members, including the CEO in both groups. Financing includes a 2018 Series A, an initial Series B closing in June 2023 and a completed USD21M Series B announced in September 2024. Strategic investments by Linearis Ventures and Zynext Ventures were announced in February and April 2025, respectively, with undisclosed amounts. Research awards and collaborative project budgets are documented separately from equity funding.

Distributed Spectrum builds software and low-cost sensors that use machine learning to detect, classify and locate radio-frequency signals for defense and electronic warfare. Its edge models process signals locally, identify nearby threats such as drones and jammers, and provide real-time alerts without requiring expensive specialist hardware or trained radio experts. Modular commercial components support sensors carried by operators, installed on vehicles, deployed as a detection mesh or integrated into existing systems.

Keenable builds independent web-search and retrieval infrastructure for AI labs, inference providers and autonomous agents. Its own index contains more than 100 billion documents and powers a search API, page-content retrieval and an MCP interface. Its SELECT web-query language extracts and combines information from many live pages into sourced tables, while its Time Machine product provides access to historical page versions. Cloud and dedicated infrastructure options support large-scale AI training and live inference.

Has experience in circuit design, signal processing and radio communications, including sensor and electronic-warfare work at Raytheon and Lockheed Martin; authored a textbook on radio systems.

Previously led Yandex Search and Ads and directed web infrastructure at Amazon AGI.

Has worked in startup strategy and operations, led a consulting firm, and worked as an engineer at Microsoft and Bridgewater.

Works on ranking models, content quality and language-model demonstrations; previously a senior machine-learning engineer at Booking.com and Yandex. His own experience record dates his Keenable role from January 2026.

Has worked in neurobiology, computational biology and machine learning, and has software-engineering experience at Google and a media startup.

Previously a principal applied scientist at Amazon AGI, building web grounding and large-scale retrieval infrastructure.

Neuroscience and digital-health company developing eye-tracking and AI tools for neurodevelopmental and neurocognitive care. BGaze Clinic measures small involuntary eye movements, called cognitive vergence, to support clinicians assessing ADHD; BGaze Focus uses gaze-controlled games for attention training through clinicians and therapists. Its research pipeline also covers autism, dyslexia and Alzheimer’s disease; these pipeline applications are not described as approved treatments. Founded in 2013 as a University of Barcelona spinout, it operates in the UK and Barcelona.

Final Frontier is a Copenhagen-based venture capital firm that invests in European pre-seed and seed companies developing space, defence and cyber technology, with a focus on the Nordic and Baltic countries and Ukraine. It backs products including drones and autonomous systems, satellite infrastructure, propulsion and defence intelligence software, and helps founders navigate technical development and defence procurement. Founded in 2024, it joined forces with Myriad Defence under the Final Frontier brand in September 2026 and is raising a second fund.

London-based venture capital firm investing at seed and Series A in digital diagnostics, digital therapeutics, medical devices, data and discovery platforms, and health AI. It helps founders commercialize and distribute health technologies through collaborations with health systems, pharmaceutical and medical-device companies. Its clinical focus includes mental health, cardiovascular and metabolic conditions, oncology and women’s health; its Special Opportunities Fund invested in Braingaze’s digital detection and treatment of neurocognitive conditions.

VORNvc is a Dortmund-based venture capital manager that pools capital from regional savings banks and entrepreneurs to finance technology startups, especially in the eastern Ruhr region. It provides up to €6 million in equity and equity-like financing, acts as lead or co-investor through successive rounds, and connects portfolio companies with regional midsize businesses. Its published investment cases span AI-controlled indoor farming, cancer therapeutics, digital identities, logistics infrastructure and advanced materials.

Healthcare leader with life-sciences strategy, consulting, market-expansion and digital-innovation experience at IQVIA, Sensirion and Siemens.

Healthcare executive and investor with experience building R&D teams and launching medicines globally. Annalisa Jenkins is a physician and biotechnology executive advising Automata on clinical development and the growth of life-sciences companies. Previously led Dimension Therapeutics and held biopharmaceutical leadership roles. Her existing RYSE affiliation is preserved; this advisory role is separate from a statutory board or personal investment.

Scientist working in scalable innovation and business transformation, with experience at Costa Coffee and Unilever.

Investment-industry finance and risk-management professional with hedge-fund and real-estate CFO experience; Canadian and US CPA qualifications.

Venture-capital investor in university technology spinouts, previously involved in ApaTech, pharmaceutical business development, Imperial incubation, MTI medical-technology investments and LifeArc seed funding.

Healthcare investor with more than 25 years of policy and distribution-contract experience, including pharma and biotech research roles at ING and S&P Global.

Finance professional with investment-banking, private-equity and venture-capital experience; Warwick MBA and Wharton executive fintech education.

Technology and media leader working in commercial transformation, product innovation and growth.

Neurobiologist and co-founder of Braingaze, leading its eye-movement biomarker technology.

Physician, scientist, engineer and investor; the firm identifies him as a Cambridge University fellow and NHS board member.

Former worldwide CEO and chairman of Saatchi & Saatchi; the published RYSE role is labelled Leadership without an additional invented corporate title.

Scientist, business-development executive and investor with experience in R&D, medical affairs, pharmaceutical partnerships, medical technology and biotech.

Technology entrepreneur and mental-health company investor and board member; previously co-founded digital platforms including GIA and Fusion.

Intellectual-property and regulated-health-products lawyer, licensed Ontario pharmacist, and registered Canadian patent and trademark agent.

Investor and biochemist, formerly a banker at Merrill Lynch, Morgan Stanley and Schroders.

Founder of the Vision Optimization Summit and filmmaker of My Neuroplastic Adventure, working in psychedelics and health optimization.